Aspirin
Small molecule targets CDX2, PTGS1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | DuoPlavin | — | 2010-03-14 | europa.eu ↗ |
| Approved | US (FDA) | PERCODAN | — | 1950-04-12 | fda.gov ↗ |
Trials 600 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 035 trials | ||||||
| Phase 0 | NCT03590821 | Dec 2027 → Jan 2028 expected | — | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07525635 | Apr 2026 → Aug 2027 expected | preeclampsia | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 0 | NCT07205250 | Feb 2026 → Jan 2028 expected | aortic disorder | The General Hospital of Western Theater Command | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06933056 | Sep 2025 → Sep 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 0 | NCT06378398 | Jun 2024 → Feb 2026 | colorectal neoplasm | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT06383650 | Jun 2024 → May 2025 | arterial disorder, vascular brain injury | London Health Sciences Centre | Unknown | No outcome recorded |
| Phase 0 | NCT06168461 | Nov 2023 → Jun 2026 overdue | preeclampsia | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05709483 | Apr 2023 → Nov 2026 expected | preeclampsia | Rockefeller University | Recruiting | No outcome recorded |
| Phase 0 | NCT05308030 | Aug 2022 → May 2023 | peripheral arterial disease | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT05056896 | Jun 2022 → Nov 2024 overdue | colorectal cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05080946 | Nov 2021 → Jul 2026 overdue | fallopian tube carcinoma, ovarian carcinoma, peritoneal carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT05105919 | Aug 2021 → Apr 2024 overdue | type 2 diabetes mellitus | Montreal Heart Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04822363 | Aug 2021 → May 2025 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT04284397 | Dec 2020 → Feb 2027 expected | — | Penn State University | Recruiting | No outcome recorded |
| Phase 0 | NCT04243278 | Sep 2020 → Dec 2022 | severe pre-eclampsia | Dr. Graeme Smith | Terminated | No outcome recorded |
| Phase 0 | NCT04464070 | Aug 2020 → Jul 2027 expected | — | Vanderbilt University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT04083950 | Dec 2019 → Jan 2022 overdue | typhoid fever | USDA, Western Human Nutrition Research Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03765619 | Jun → Nov 2019 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT03900871 | Apr 2019 → Apr 2020 | — | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03771651 | Mar 2019 → May 2022 overdue | fallopian tube cancer, salpingitis | University of Oklahoma | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03377543 | Jun 2018 → Dec 2025 overdue | inflammatory disease | Beth Israel Deaconess Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03378297 | May 2018 → Jan 2023 | ovarian cancer | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03100123 | Nov 2017 → Oct 2019 | antiphospholipid syndrome, pregnancy disorder with abortive outcome | Ottawa Hospital Research Institute | Terminated | No outcome recorded |
| Phase 0 | NCT03051646 | Jan → May 2017 | — | Columbia University | Completed | No outcome recorded |
| Phase 0 | NCT03130153 | Jan 2016 → Jul 2017 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 0 | NCT02047539 | Jan 2015 → Mar 2021 | early-onset schizophrenia | Yale University | Terminated | No outcome recorded |
| Phase 0 | NCT02285738 | Dec 2014 → Jul 2017 | cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02268565 | Oct 2014 → Oct 2016 | insomnia | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT01817400 | Mar 2013 → Dec 2014 | female infertility, obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 0 | NCT01796951 | Feb 2013 → Feb 2016 | nicotine dependence | Vanderbilt University | Completed | No outcome recorded |
| Phase 0 | NCT01707823 | Oct 2012 → Jun 2018 | lung adenocarcinoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT00727948 | Jul 2008 → Dec 2010 | breast cancer | University of Vermont | Completed | No outcome recorded |
| Phase 0 | NCT00688961 | Jun → Aug 2007 | — | Sanford Research | Completed | No outcome recorded |
| Phase 0 | NCT00753935 | Jun 2006 → Aug 2011 | coronary artery disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 0 | NCT05428072 | Jan 2003 → Mar 2015 | alcoholic liver disease | Rush University Medical Center | Completed | No outcome recorded |
| Phase 161 trials | ||||||
| Phase 1 | NCT07652723 | May → Oct 2026 expected | — | Bayer | Recruiting | No outcome recorded |
| Phase 1 | NCT07265466 | Nov 2025 → Mar 2026 overdue | — | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07323680 | Jun → Jul 2025 | — | Rhoshan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT06655194 | Feb → Apr 2025 | platelet aggregation, spontaneous | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT07444164 | Jan 2025 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT06444178 | Sep 2024 → Apr 2025 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06277609 | Feb → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05702463 | Jun 2023 → Jun 2027 expected | aspirin resistance, platelet aggregation, spontaneous, type 2 diabetes mellitus | Montreal Heart Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05625347 | Mar → Jun 2023 | obstructive lung disease, restrictive pulmonary disease | Vectura Limited | Terminated | No outcome recorded |
| Phase 1 | NCT05699070 | Feb → Apr 2023 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05625334 | Oct 2022 → Mar 2023 | — | Vectura Limited | Completed | No outcome recorded |
| Phase 1 | NCT05304845 | Mar → May 2022 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT05166096 | Dec 2021 → May 2022 | — | Rhoshan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT04809818 | Mar → Aug 2021 | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04792723 | Mar → Jul 2021 | cardiovascular disorder | Vita Green Health Products Co. Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04328883 | Jul → Oct 2019 | platelet aggregation, spontaneous | Inova Health Care Services | Completed | No outcome recorded |
| Phase 1 | NCT03728179 | Jan 2019 → Oct 2023 | cancer | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT03698513 | Oct 2018 → Feb 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03245489 | Mar 2018 → Nov 2023 | head and neck cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT04976465 | Jan 2018 → Jul 2025 overdue | pregnancy disorder, systemic lupus erythematosus | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 1 | NCT03341390 | Oct → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03225352 | Aug → Oct 2017 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03471169 | Apr 2017 → Dec 2018 | cerebrovascular disorder | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 1 | NCT02554721 | Aug 2015 → Mar 2018 | — | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02370680 | Feb → Jul 2015 | cardiovascular disorder | New Haven Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02229461 | Feb → May 2015 | hematologic disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02080858 | May → Oct 2014 | acute coronary syndrome, atrial fibrillation | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT01847404 | May → Jun 2013 | peptic ulcer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02060396 | Apr → Jun 2013 | — | Aragon Institute of Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01768637 | Jan 2013 → Apr 2014 | chronic kidney disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01708369 | Feb → May 2012 | — | University of Tennessee | Completed | No outcome recorded |
| Phase 1 | NCT01448031 | Nov 2011 → Apr 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01710072 | Aug 2011 → Aug 2014 | — | University of Iowa | Completed | No outcome recorded |
| Phase 1 | NCT01281111 | Feb → Mar 2011 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01663038 | Dec 2010 → Jan 2011 | coronary artery disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01210339 | Nov 2010 → Aug 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01244100 | Oct → Dec 2010 | — | PLx Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01108588 | Jun → Aug 2010 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01238185 | Feb 2010 → Oct 2011 | preneoplastic lesion | Institute of Head and Neck Studies and Education, United Kingdom | Completed | No outcome recorded |
| Phase 1 | NCT01081353 | Feb → Mar 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01072604 | Jul → Aug 2009 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01409616 | Apr → Sep 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT04008979 | Feb → Jun 2008 | — | PLx Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00632086 | Feb 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT01424332 | Dec 2007 → Mar 2008 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00417898 | Mar 2007 → Dec 2012 | ischemic stroke | Hadassah Medical Organization | Withdrawn | No outcome recorded |
| Phase 1 | NCT00441519 | Feb → Apr 2007 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00425074 | Jan → Jun 2007 | cardiovascular disorder | Rottapharm Spain | Completed | No outcome recorded |
| Phase 1 | NCT00442052 | Nov 2006 → Jan 2007 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00566904 | Sep 2006 → Aug 2008 | postherpetic neuralgia | Biomedical Development Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00363753 | Aug 2006 → Mar 2007 | aspirin resistance, transient ischemic attack | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1 | NCT00587496 | Apr 2006 → Jul 2008 | herpes simplex infectious disease | National Eye Institute (NEI) | Unknown | No outcome recorded |
| Phase 1 | NCT00265408 | Dec 2005 → Mar 2007 | ischemic stroke | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1 | NCT00731302 | Apr 2005 → Apr 2017 | systemic lupus erythematosus | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00178464 | Mar 2005 → Apr 2009 | sickle cell disease | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT00948987 | Sep 2004 → Oct 2009 | aspirin resistance | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT02262793 | May → Jul 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02187562 | Jul → Aug 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT02268773 | Jan → May 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02278302 | Aug 1999 → Mar 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06417411 | Mar 2024 → Mar 2026 overdue | preeclampsia, sickle cell disease | Instituto Nacional de Investigacao em Saude, Angola | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04645004 | Dec 2020 → Jan 2024 | preeclampsia | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1/2 | NCT04031729 | Sep 2019 → Feb 2023 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02401269 | Apr 2015 → Jan 2016 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1/2 | NCT00872534 | Jan → Jul 2009 | gastrointestinal mucositis | PLx Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT00771914 | Nov 2008 → Jan 2009 | — | University of Rochester | Completed | No outcome recorded |
| Phase 1/2 | NCT00174902 | Oct 2003 → Aug 2004 | arteriosclerosis disorder | Swiss Federal Institute of Technology | Unknown | No outcome recorded |
| Phase 290 trials | ||||||
| Phase 2 | NCT07663825 | Sep 2026 → Sep 2030 expected | congenital vascular malformation | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07661459 | Jun 2026 → Jul 2027 expected | cancer | Val Adams | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06866964 | Aug 2025 → Aug 2029 expected | germ cell tumor, testicular cancer | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06728072 | Mar 2025 → Jul 2035 expected | colorectal cancer | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 2 | NCT06554535 | Oct 2024 → Oct 2026 expected | small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06531525 | Aug 2024 → Dec 2026 expected | pregnancy disorder, protein S deficiency | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06425133 | Jul 2024 → Sep 2027 expected | colorectal cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2 | NCT05775965 | May 2024 → Mar 2025 overdue | osteoporosis | University of Calgary | Recruiting | No outcome recorded |
| Phase 2 | NCT05637567 | Apr 2024 → Sep 2028 expected | pancreas disorder | German Cancer Research Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05567562 | Mar 2024 → Feb 2025 | pulmonary emphysema | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06228820 | Jan → Dec 2024 | platelet disorder, undefined | The University of The West Indies | Completed | No outcome recorded |
| Phase 2 | NCT04188119 | Dec 2023 → Sep 2024 | breast cancer | The Christie NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 2 | NCT06018688 | Sep 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05924971 | Jul 2023 → Dec 2026 expected | severe pre-eclampsia | MemorialCare Health System | Recruiting | No outcome recorded |
| Phase 2 | NCT06254391 | Jul 2023 → Jul 2025 | acute coronary syndrome, myocardial infarction | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 2 | NCT05557877 | Mar 2023 → Jan 2027 expected | breast carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT04912505 | Jan 2023 → Jan 2024 | thrombocytopenic purpura | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2 | NCT05514938 | Nov 2022 → May 2025 | acute coronary syndrome, coronary artery disorder, lip disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05546320 | Oct 2022 → Mar 2025 | migraine disorder, patent foramen ovale | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05402124 | Jul 2022 → Mar 2023 | adenomatous colon polyp, colorectal cancer | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT05093790 | Mar → Nov 2022 | coronary artery disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT04824911 | Mar 2021 → Feb 2025 | stroke disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04575519 | Mar 2021 → Dec 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Germans Trias i Pujol Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT04295486 | Mar 2021 → Mar 2027 expected | venous thromboembolism | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT05775536 | Jan → Nov 2021 | dry eye syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT04534218 | Oct 2020 → Dec 2023 | colorectal cancer, metastatic malignant neoplasm | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2 | NCT04402385 | Aug 2020 → Jun 2022 | hypertensive urgency, preeclampsia | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT04466670 | Jul 2020 → Dec 2021 | COVID-19 | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04363840 | May → Dec 2020 | COVID-19, disseminated intravascular coagulation, vitamin D deficiency | Louisiana State University Health Sciences Center in New Orleans | Withdrawn | No outcome recorded |
| Phase 2 | NCT04128956 | Mar 2020 → Feb 2024 | venous thromboembolism | University of Zurich | Terminated | No outcome recorded |
| Phase 2 | NCT05525156 | Mar 2020 → Jun 2022 | HIV infectious disease, cardiovascular disorder | Muhimbili University of Health and Allied Sciences | Suspended | No outcome recorded |
| Phase 2 | NCT03899987 | Nov 2019 → Apr 2027 expected | prostate adenocarcinoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03661463 | Oct → Dec 2019 | brain aneurysm | University Hospital Southampton NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT04038489 | Oct 2019 → Apr 2023 | estrogen-receptor positive breast cancer | University of Virginia | Withdrawn | No outcome recorded |
| Phase 2 | NCT03794596 | Sep 2019 → Feb 2021 | breast cancer | The Christie NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 2 | NCT04066725 | Jul 2019 → Mar 2021 | cutaneous melanoma | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT03654105 | Jul 2019 → Dec 2024 overdue | lung cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03927313 | Jun 2019 → Mar 2021 | HIV infectious disease, meningeal tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 2 | NCT03957902 | May 2019 → May 2025 overdue | colorectal cancer | Aragon Health Research Institute (IISAragon) | Recruiting | No outcome recorded |
| Phase 2 | NCT03893630 | Apr 2019 → Jul 2022 | preeclampsia | John O'Brien, MD | Completed | No outcome recorded |
| Phase 2 | NCT03329599 | Feb 2019 → Dec 2021 | atherosclerosis | Northern California Institute of Research and Education | Completed | No outcome recorded |
| Phase 2 | NCT04184921 | Jan 2019 → Jun 2023 | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT03606642 | Nov 2018 → Dec 2021 | atherosclerosis, coronary artery disorder | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03638297 | Aug 2018 → Aug 2022 | colorectal cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03079999 | Jun 2018 → Aug 2026 overdue | NF2-related schwannomatosis, acoustic neuroma | Massachusetts Eye and Ear Infirmary | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03396952 | Apr 2018 → Apr 2020 | cutaneous melanoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02965703 | Jan 2018 → Jan 2023 overdue | colorectal adenoma, colorectal carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03543683 | Jan 2018 → Jan 2023 | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT03290820 | Jan 2018 → Sep 2024 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03170115 | Nov 2017 → Jan 2020 | rectum adenocarcinoma | Brazilian National Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03356769 | Nov 2017 → Nov 2021 | cognitive disorder, epilepsy, skin disorder, tuberous sclerosis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02901067 | Feb 2017 → May 2021 | venous thromboembolism | Denver Health and Hospital Authority | Terminated | No outcome recorded |
| Phase 2 | NCT02659384 | Dec 2016 → Jun 2021 | ovarian neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT04062032 | Sep 2016 → Feb 2019 | cutaneous melanoma | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT02791958 | Mar 2016 → Oct 2017 | hypertensive disorder | Ferrer Internacional S.A. | Unknown | No outcome recorded |
| Phase 2 | NCT02521285 | Jan 2016 → Jun 2019 overdue | Barrett esophagus, esophageal adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02348203 | Jan 2016 → Feb 2019 | nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02602938 | Nov 2015 → Nov 2016 | — | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03487406 | Sep 2015 → Nov 2017 | chronic obstructive pulmonary disease | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT02333123 | Jul 2015 → Aug 2016 | ulcer of lower limbs | St George's, University of London | Terminated | No outcome recorded |
| Phase 2 | NCT02420652 | Jun 2015 → Dec 2019 | prostate carcinoma | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 2 | NCT02326350 | Feb 2015 → Nov 2018 | adult acute respiratory distress syndrome | Belfast Health and Social Care Trust | Terminated | No outcome recorded |
| Phase 2 | NCT02169271 | Nov 2014 → Jul 2018 | nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02227368 | Oct 2014 → May 2016 | peripheral arterial disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT02237365 | Oct 2014 → Jun 2016 | meningeal tuberculosis | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 2 | NCT02565693 | Sep 2014 → Jan 2021 | atrial fibrillation, intracerebral hemorrhage | UMC Utrecht | Completed | No outcome recorded |
| Phase 2 | NCT02123849 | Jun 2014 → Sep 2016 | lung carcinoma, nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02285751 | Nov 2012 → Jul 2020 | critical illness polyneuropathy | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT01616615 | Sep 2012 → Apr 2015 | placental insufficiency | Sara Varea | Completed | No outcome recorded |
| Phase 2 | NCT01618006 | Jan 2012 → Apr 2013 | postoperative ventricular dysfunction | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01504867 | Jan 2012 → Sep 2015 | acute respiratory distress syndrome | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01431053 | Jul 2011 → Jul 2014 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01005290 | Oct 2009 → Oct 2010 | hypertensive disorder | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT01004705 | Sep 2009 → Mar 2011 | low density lipoprotein cholesterol, mild elevation of | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT00983580 | Aug 2009 → Oct 2016 | adenomatous colon polyp | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00567307 | Jan → Dec 2009 | cardiovascular disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00861341 | Dec 2008 → Jun 2010 | blood platelet disease, diabetes mellitus | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00578721 | Sep 2008 → Nov 2013 | colorectal cancer | University of California, Irvine | Completed | No outcome recorded |
| Phase 2 | NCT00623779 | Oct 2007 → Oct 2008 | persistent atrial fibrillation | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00474903 | Apr 2007 → Mar 2011 | Barrett esophagus, esophageal cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00468910 | Mar 2007 → Dec 2009 | colon carcinoma, precancerous condition, rectal cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00603590 | Nov 2006 → Jun 2008 | heart disorder, hyperlipidemia, hypertensive disorder | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00263211 | Jan 2006 → Sep 2009 | breast cancer | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT01227629 | Sep 2003 → Nov 2004 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00406991 | Jun 2003 → Mar 2006 | diabetes mellitus, diabetic retinopathy | Schepens Eye Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00405613 | May 2003 → Dec 2005 | hemorrhagic disease | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00054938 | Mar 2003 → Dec 2005 | systemic lupus erythematosus | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00105209 | Apr 2002 → Dec 2003 | pulmonary arterial hypertension | Kawut, Steven, MD | Completed | No outcome recorded |
| Phase 2 | NCT00020189 | Jun 2000 → Aug 2004 | head and neck cancer, thrombotic disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00000527 | Aug 1986 → Nov 1998 | carotid stenosis, heart disorder | Emory University | Completed | No outcome recorded |
| Phase 2/322 trials | ||||||
| Phase 2/3 | NCT07337655 | Oct 2026 → Sep 2030 expected | — | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06068439 | Jan 2024 → Jan 2027 expected | diabetic kidney disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05865548 | May 2023 → Aug 2024 | oral cavity cancer | Banaras Hindu University | Completed | No outcome recorded |
| Phase 2/3 | NCT05462613 | May 2023 → Nov 2029 expected | colorectal cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05568147 | Oct 2022 → Sep 2027 expected | thrombotic thrombocytopenic purpura | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04802785 | Jun → Jul 2021 | — | Dinara Zhumanbayeva | Unknown | No outcome recorded |
| Phase 2/3 | NCT04768179 | Feb → Jun 2021 | COVID-19 | Makerere University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04491695 | Sep 2020 → Dec 2022 | stroke disorder | Capital Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04365309 | Feb → Apr 2020 | COVID-19 | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03961360 | May 2019 → Apr 2023 | obesity disorder, preeclampsia | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2/3 | NCT03491410 | Jun 2018 → Dec 2019 | breast cancer | Centro Hospitalar Lisboa Ocidental | Unknown | No outcome recorded |
| Phase 2/3 | NCT03326791 | Dec 2017 → Feb 2022 overdue | metastasis from malignant tumor of colon | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02685748 | Jul 2017 → Dec 2019 | schizophrenia | Clinic for Psychiatric Disorders, Dr Laza Lazarevic | Completed | No outcome recorded |
| Phase 2/3 | NCT03093207 | May 2017 → Oct 2018 | periodontitis, aggressive, residual stage angle-closure glaucoma | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT03093246 | May 2017 → Oct 2018 | periodontitis, aggressive | São Paulo State University | Completed | No outcome recorded |
| Phase 2/3 | NCT03103152 | Dec 2016 → Mar 2020 | prostate cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2/3 | NCT02482857 | Dec 2011 → Jul 2015 | coronary artery disorder | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01012349 | Feb → May 2011 | — | Azidus Brasil | Unknown | No outcome recorded |
| Phase 2/3 | NCT00501254 | Feb 2005 → Feb 2007 | cardiovascular disorder | Rottapharm Spain | Completed | No outcome recorded |
| Phase 2/3 | NCT00222677 | May 2004 → Jan 2012 | atherosclerosis, pulmonary embolism, vein disorder, venous thromboembolism | University Of Perugia | Unknown | No outcome recorded |
| Phase 2/3 | NCT00201461 | Jun 2003 → Apr 2010 | patent foramen ovale, transient ischemic attack | NMT Medical | Unknown | No outcome recorded |
| Phase 2/3 | NCT00272324 | Feb 1992 → Jan 2007 | colon adenoma, colorectal cancer, polyp of colon | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 3129 trials | ||||||
| Phase 3 | NCT07665853 | Jul 2026 → May 2028 expected | preeclampsia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07524335 | May 2026 → May 2027 expected | atherosclerotic cardiovascular disease, coronary artery disorder | Montreal Heart Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07113158 | Apr 2026 → Apr 2029 expected | sudden sensorineural hearing loss | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05963568 | Apr 2026 → Jan 2029 expected | stroke disorder | Northern California Institute of Research and Education | Recruiting | No outcome recorded |
| Phase 3 | NCT06774846 | Feb 2026 → May 2029 expected | pneumonia | Centre Hospitalier Universitaire Dijon | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06980025 | Jul 2025 → Dec 2028 expected | obstetric disorder | The George Washington University Biostatistics Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06930885 | Jun 2025 → May 2031 expected | atherosclerotic cardiovascular disease | Hospital do Coracao | Recruiting | No outcome recorded |
| Phase 3 | NCT06952712 | May 2025 → May 2028 expected | preeclampsia | FANG HE | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06494878 | Apr 2025 → Aug 2030 expected | venous thromboembolism | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06518317 | Nov 2024 → Nov 2028 expected | — | University Hospital, Caen | Recruiting | No outcome recorded |
| Show all 129 trials opens the full record — a long page | ||||||
| Phase 4155 trials | ||||||
| Phase 4 | NCT07683923 | Mar 2027 → Feb 2033 expected | acute coronary syndrome, idiopathic spontaneous coronary artery dissection | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07496281 | Mar 2027 → Feb 2032 expected | atrial fibrillation, coronary artery disorder | Ewha Womans University Mokdong Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07281547 | Aug 2026 → Jun 2027 expected | endometrial carcinoma | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07431762 | Jun 2026 → Oct 2030 expected | cardiac valvular defect | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07642427 | Jun 2026 → May 2029 expected | acquired aneurysmal subarachnoid hemorrhage, brain ischemia | Ganzhou City People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07602257 | Jun 2026 → Dec 2029 expected | — | Ottawa Heart Institute Research Corporation | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644234 | Jun 2026 → Dec 2028 expected | transient ischemic attack | Sichuan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07563673 | May 2026 → Sep 2027 expected | cerebral infarction | Beijing Chao Yang Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07592507 | May 2026 → Feb 2032 expected | coronary artery disorder | Daejeon St. Mary's hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07373756 | Jan → Dec 2026 expected | hypertension, pregnancy-induced | Dr. Sunita Pun | Not yet recruiting | No outcome recorded |
| Show all 155 trials opens the full record — a long page | ||||||
| Phase not applicable101 trials | ||||||
| — | NCT06937372 | Aug 2026 → Oct 2027 expected | venous thromboembolism | Queen Mary University of London | Not yet recruiting | No outcome recorded |
| — | NCT07677410 | Jul 2026 → Jul 2029 expected | aortic valve insufficiency | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07658989 | May 2026 → Jan 2030 expected | cardiac valvular defect, pregnancy disorder | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| — | NCT07432516 | Feb 2026 → Jun 2033 expected | coronary artery disorder | Yonsei University | Not yet recruiting | No outcome recorded |
| — | NCT06535568 | Jan 2026 → Jan 2028 expected | acute coronary syndrome, arterial occlusion, atherosclerosis, coronary stenosis | Fondazione Ricerca e Innovazione Cardiovascolare ETS | Recruiting | No outcome recorded |
| — | NCT07041385 | Nov 2025 → Jun 2027 expected | preeclampsia | Shalamar Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07240454 | Oct 2025 → Dec 2027 expected | — | Tao Liu | Recruiting | No outcome recorded |
| — | NCT07198529 | Sep 2025 → Sep 2029 expected | coronary artery disorder | Korea University Guro Hospital | Recruiting | No outcome recorded |
| — | NCT07066176 | Jul → Aug 2025 | — | Laval University | Completed | No outcome recorded |
| — | NCT07613840 | Apr 2025 → Apr 2027 expected | peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
| — | NCT07673185 | Jan 2025 → Jul 2026 overdue | periodontitis | Al-Azhar University | Recruiting | No outcome recorded |
| — | NCT06276374 | Jul 2024 → Nov 2029 expected | carotid artery disorder | Woo-Keun Seo | Recruiting | No outcome recorded |
| — | NCT06108947 | Jan 2024 → Dec 2026 expected | preeclampsia | St. Olavs Hospital | Recruiting | No outcome recorded |
| — | NCT05761704 | Nov 2023 → Nov 2024 | atrial fibrillation | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06185621 | Nov 2023 → Nov 2026 expected | aspirin resistance, recurrent acute pancreatitis | Air Force Military Medical University, China | Recruiting | No outcome recorded |
| — | NCT06058130 | Sep 2023 → Oct 2025 | atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06053021 | Sep 2023 → Oct 2025 | ischemic stroke, thrombocytopenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05936606 | Aug 2023 → May 2027 expected | coronary artery disorder | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05580523 | Jul 2023 → Jan 2025 | preeclampsia | Chinese University of Hong Kong | Unknown | No outcome recorded |
| — | NCT06261203 | Jul 2023 → Jul 2025 | preeclampsia | Egymedicalpedia | Unknown | No outcome recorded |
| — | NCT05825391 | May → Oct 2023 | brain aneurysm | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT07338331 | Apr 2023 → Apr 2025 | NAFLD1, type 2 diabetes mellitus | Galala University | Completed | No outcome recorded |
| — | NCT07523841 | Apr 2023 → Apr 2027 expected | periodontitis | Hanoi Medical University | Active not recruiting | No outcome recorded |
| — | NCT07087067 | Feb 2023 → Feb 2025 | preeclampsia | Galala University | Completed | No outcome recorded |
| — | NCT05546957 | Jan → Apr 2023 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| — | NCT07597239 | Dec 2022 → Feb 2026 overdue | arterial occlusion, peripheral arterial disease, thrombotic disease | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| — | NCT05419583 | Nov 2022 → Jun 2024 | myocardial infarction | University of Edinburgh | Completed | No outcome recorded |
| — | NCT05623904 | Oct 2022 → Dec 2025 | carotid stenosis | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT06710600 | Sep 2022 → Apr 2024 | photosensitivity disease | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT05353140 | Sep 2022 → Sep 2028 expected | atrial fibrillation | Xijing Hospital | Recruiting | No outcome recorded |
| — | NCT04694248 | Nov 2021 → Dec 2026 expected | May-Thurner syndrome, iliac vein thrombophlebitis, venous thromboembolism | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| — | NCT04971356 | Nov 2021 → Mar 2024 overdue | acute coronary syndrome | Xijing Hospital | Active not recruiting | No outcome recorded |
| — | NCT05036109 | Oct 2021 → Feb 2026 | colon carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT04995159 | Sep 2021 → Jan 2026 overdue | coronary artery disorder | Lepu Medical Technology (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT05058924 | Aug 2021 → Feb 2024 | venous thromboembolism | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| — | NCT06442709 | Aug 2021 → Jul 2024 | nasopharyngeal carcinoma | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| — | NCT04820972 | May 2021 → Feb 2023 | intracerebral hemorrhage | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT05994287 | Jan 2021 → Jan 2022 | — | Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty | Completed | No outcome recorded |
| — | NCT04269863 | Nov 2020 → Nov 2021 | peripheral arterial disease | Unity Health Toronto | Unknown | No outcome recorded |
| — | NCT03821883 | Jun 2020 → Jun 2022 | atrial fibrillation, hemorrhagic disease, stroke disorder | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT04330729 | Apr 2020 → Dec 2026 expected | erythropoietin polycythemia | Zealand University Hospital | Recruiting | No outcome recorded |
| — | NCT04338919 | Apr 2020 → Apr 2021 | acute coronary syndrome | Fujian Medical University | Unknown | No outcome recorded |
| — | NCT04333407 | Apr 2020 → Nov 2021 | COVID-19 | Imperial College London | Terminated | No outcome recorded |
| — | NCT04121611 | Oct 2019 → Oct 2021 | basilar artery occlusion | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| — | NCT03971500 | Aug 2019 → Oct 2023 overdue | coronary artery disorder | Nanjing First Hospital, Nanjing Medical University | Active not recruiting | No outcome recorded |
| — | NCT04012268 | Jul 2019 → Nov 2020 | Moyamoya disease | Capital Medical University | Completed | No outcome recorded |
| — | NCT03797651 | Apr 2019 → Apr 2025 | acute coronary syndrome | Yonsei University | Unknown | No outcome recorded |
| — | NCT03825757 | Jan 2019 → Jun 2023 | chronic rhinosinusitis | Sanna Salmi | Completed | No outcome recorded |
| — | NCT03450317 | Mar 2018 → Dec 2020 | — | Chinese University of Hong Kong | Unknown | No outcome recorded |
| — | NCT03266731 | Jan 2018 → Jan 2019 | ischemic stroke | Assiut University | Unknown | No outcome recorded |
| — | NCT03318744 | Jan 2018 → Jul 2021 | brain infarction | First People's Hospital of Shenyang | Unknown | No outcome recorded |
| — | NCT03279809 | Oct 2017 → Sep 2020 | extrahepatic cholestasis | Woo Hyun Paik | Terminated | No outcome recorded |
| — | NCT03306550 | Oct 2017 → Apr 2018 | intermediate coronary syndrome | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| — | NCT03184805 | Jun 2017 → Apr 2018 | coronary artery disorder | Yonsei University | Terminated | No outcome recorded |
| — | NCT03023020 | Apr 2017 → Apr 2021 | bleeding disorder, vascular-type, coronary artery disorder | ECRI bv | Completed | No outcome recorded |
| — | NCT03583229 | Oct 2016 → Oct 2021 | coronary artery disorder, platelet disorder, undefined | Aarhus University Hospital | Unknown | No outcome recorded |
| — | NCT02922673 | Sep → Dec 2016 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT05604118 | Aug 2016 → Aug 2018 | blood platelet disease | Cardiff University | Completed | No outcome recorded |
| — | NCT02921360 | Aug 2016 → Dec 2018 | brain ischemia, ischemic stroke | City Clinical Hospital No. 67, Moscow, Russia | Unknown | No outcome recorded |
| — | NCT02696226 | Feb 2016 → Jul 2017 | aortic valve disorder | The Cleveland Clinic | Terminated | No outcome recorded |
| — | NCT02084615 | Aug 2014 → Aug 2016 | — | Jesse Brown VA Medical Center | Unknown | No outcome recorded |
| — | NCT02209909 | Jul 2014 → Sep 2015 | coronary artery disorder | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02079077 | Apr 2014 → Dec 2015 | HIV infectious disease | University of Manitoba | Completed | No outcome recorded |
| — | NCT02079194 | Mar 2014 → Jul 2018 | coronary artery disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT04371874 | Jan 2014 → Jul 2017 | hypertensive disorder | First Affiliated Hospital Xi'an Jiaotong University | Completed | No outcome recorded |
| — | NCT02359643 | May 2013 → Apr 2017 | Kawasaki disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT02802072 | Jan 2013 → Jan 2014 | carotid stenosis | Beijing Chao Yang Hospital | Completed | No outcome recorded |
| — | NCT01763606 | Dec 2012 → Apr 2019 | — | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT01506505 | Jul 2012 → Jul 2013 | cerebrovascular disorder, peripheral arterial disease | UMC Utrecht | Completed | No outcome recorded |
| — | NCT01465256 | Apr 2012 → Jun 2014 | — | Soonchunhyang University Hospital | Unknown | No outcome recorded |
| — | NCT01547390 | Mar 2012 → Jul 2015 | preeclampsia | Washington University School of Medicine | Terminated | No outcome recorded |
| — | NCT01096706 | Jul 2011 → Jan 2012 | heart disorder, vascular disorder | University of Edinburgh | Completed | No outcome recorded |
| — | NCT02744716 | May 2011 → Jan 2016 | adhesions of uterus | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| — | NCT01612247 | Feb 2011 → Feb 2013 | breast cancer | University of Vermont | Unknown | No outcome recorded |
| — | NCT01375400 | Dec 2010 → Jul 2011 | ischemic stroke | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| — | NCT01257893 | Nov 2010 → Oct 2011 | migraine disorder | Swedish Medical Center | Withdrawn | No outcome recorded |
| — | NCT01696760 | Oct 2010 → Dec 2012 | bone neoplasm, musculoskeletal system cancer, soft tissue sarcoma, venous thromboembolism | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT01264640 | Jul 2010 → Feb 2011 | — | University of Rostock | Unknown | No outcome recorded |
| — | NCT01050153 | Mar 2010 → Dec 2011 | venous thromboembolism | Denver Health and Hospital Authority | Completed | No outcome recorded |
| — | NCT01066923 | Feb 2010 → Jun 2011 | exercise-induced malignant hyperthermia | Dave Hostler | Completed | No outcome recorded |
| — | NCT00942617 | Jul 2009 → Jun 2012 | platelet aggregation, spontaneous | Vanderbilt University | Withdrawn | No outcome recorded |
| — | NCT00898222 | May → Aug 2009 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT02384070 | Jan 2009 → Dec 2013 | coronary artery disorder | Odessa Heart Institute | Completed | No outcome recorded |
| — | NCT01212302 | Oct 2008 → Mar 2010 | coronary artery disorder | Ruhr University of Bochum | Completed | No outcome recorded |
| — | NCT02823743 | Mar 2008 → Apr 2016 | habitual spontaneous abortion | Göteborg University | Completed | No outcome recorded |
| — | NCT00578760 | Feb 2008 → Feb 2010 | platinum-induced ototoxicity | University Health Network, Toronto | Unknown | No outcome recorded |
| — | NCT02261025 | Jan 2008 → Sep 2014 | — | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT01361620 | Dec 2007 → Apr 2011 | blood platelet disease | George Washington University | Completed | No outcome recorded |
| — | NCT00563875 | Nov 2007 → Jun 2008 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT01061034 | Mar → Jun 2007 | — | Assaf-Harofeh Medical Center | Completed | No outcome recorded |
| — | NCT00389129 | Nov 2006 → Mar 2007 | aspirin resistance | University of Aarhus | Completed | No outcome recorded |
| — | NCT00418860 | Sep 2006 → Apr 2008 | coronary artery disorder | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00536068 | Aug 2006 → Aug 2007 | vascular hemostatic disease | Kantonsspital Graubünden | Completed | No outcome recorded |
| — | NCT00518141 | Mar 2006 → May 2009 | — | Sykehuset Telemark | Completed | No outcome recorded |
| — | NCT00898950 | Aug 2004 → Jul 2006 | type 2 diabetes mellitus | University of Portsmouth | Completed | No outcome recorded |
| — | NCT00646906 | Jun 2004 → Jan 2012 | arthritic joint disease, myocardial infarction | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT00494156 | Jul 2003 → Jul 2008 | arterial disorder | C. Clay Cothren, MD | Withdrawn | No outcome recorded |
| — | NCT00153725 | Feb 2003 → Sep 2006 | cerebrovascular disorder | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT00262275 | Jul 2002 → Jul 2004 | ischemic disease | Papworth Hospital NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT00033319 | May 1997 → ? | colorectal cancer | Queen's Medical Center | Unknown | No outcome recorded |
| — | NCT00382421 | Feb 1992 → Apr 2006 | myocardial ischemia | Luzerner Kantonsspital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 733 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 013 trials | ||||||
| Phase 0 | NCT06339021 Background | Apr 2024 → Dec 2026 expected | ST-elevation myocardial infarction | Shenyang Northern Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04040465 Comparator | Feb → Oct 2021 | aspirin resistance | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT04153760 Comparator | Oct 2020 → Sep 2023 | venous thromboembolism | University of Calgary | Completed | No outcome recorded |
| Phase 0 | NCT04535804 Comparator | Oct 2020 → Sep 2022 | adenomyosis | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04146532 Comparator | Oct 2019 → Apr 2022 | — | Ohio State University | Completed | No outcome recorded |
| Phase 0 | NCT06419283 Background | Aug 2019 → Dec 2022 | cerebral artery occlusion | Huizhou Municipal Central Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04379999 Comparator | Sep 2018 → Aug 2025 | Lynch syndrome | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT05278637 Comparator | Nov 2013 → Dec 2016 | aspirin resistance, nuclear ribonucleic acid, platelet aggregation, spontaneous | Duke University | Completed | No outcome recorded |
| Phase 0 | NCT02062255 Comparator | Oct 2013 → Apr 2016 | female breast carcinoma | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT02029118 Background | Oct 2012 → May 2015 | — | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 0 | NCT01731236 Comparator | Feb 2011 → Dec 2027 expected | — | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 0 | NCT00797056 Background | Apr 2008 → Apr 2012 | peripheral vascular disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT00960817 Comparator | — | coronary artery disorder | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
| Phase 142 trials | ||||||
| Phase 1 | NCT03186456 Background | Dec 2026 → Jun 2027 | cerebral infarction | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT06565728 Comparator | Nov 2022 → May 2023 | fetal growth restriction | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT06106880 Comparator | May 2022 → Apr 2023 | Achoo syndrome, common cold, headache disorder, pharyngitis +1 | Applied Biological Laboratories Inc | Completed | No outcome recorded |
| Phase 1 | NCT04945616 Background | Jul → Oct 2021 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04588727 Background | Oct 2020 → Jan 2022 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03805932 Background | Oct 2019 → Jul 2023 overdue | hairy cell leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02761486 Comparator | Aug 2016 → Jun 2018 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT03078257 Background | Jan 2016 → Nov 2017 | coronary artery disorder | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT02439190 Comparator | Sep 2015 → Mar 2016 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02209350 Comparator | Aug 2015 → Nov 2020 | — | Meshalkin Research Institute of Pathology of Circulation | Completed | No outcome recorded |
| Phase 1 | NCT02419820 Background | Mar 2015 → Apr 2016 | acute coronary syndrome | IlDong Pharmaceutical Co Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT02394093 Comparator | Feb → Mar 2015 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02341638 Background | Sep 2014 → Sep 2015 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02034292 Background | Feb → Mar 2014 | acute coronary syndrome | IlDong Pharmaceutical Co Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT02071004 Background | Jan → Feb 2014 | ischemic stroke | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT03197779 Background | Nov 2013 → Feb 2016 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02243137 Comparator | May 2013 → Jun 2014 | — | David Vivas | Completed | No outcome recorded |
| Phase 1 | NCT01744288 Background | Dec 2012 → Apr 2014 | platelet aggregation, spontaneous | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01657071 Comparator | Mar → Apr 2012 | acute coronary syndrome | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01518231 Comparator | Jan → Dec 2012 | stroke disorder | Zhejiang Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01486433 Background | Nov 2011 → Mar 2012 | hypertriglyceridemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01733485 Comparator | Oct 2011 → Sep 2016 | asthma | Sally E. Wenzel MD | Completed | No outcome recorded |
| Phase 1 | NCT01526122 Comparator | Sep → Dec 2011 | atherosclerosis | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01496261 Comparator | Aug → Sep 2011 | coronary artery disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01422109 Comparator | Jul → Nov 2011 | acute coronary syndrome | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01388660 Comparator | Jun 2011 → Sep 2014 | coronary artery disorder | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT01557335 Comparator | Nov 2010 → Feb 2011 | platelet aggregation, spontaneous | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT01199328 Comparator | Sep → Nov 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01762787 Comparator | Aug 2010 → Jan 2011 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01188304 Background | Jul → Oct 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01047722 Comparator | Jan 2010 → Oct 2015 | — | Klein, Jeffrey A., M.D. | Unknown | No outcome recorded |
| Phase 1 | NCT01012219 Background | Nov 2009 → Mar 2010 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00984113 Background | Sep → Dec 2009 | impaired renal function disease | Portola Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00935506 Background | Jul → Oct 2009 | cardiovascular disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00700687 Comparator | Jun → Jul 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT01042704 Background | Feb 2008 → Jan 2011 | plasma cell myeloma | Robert Redner, MD | Completed | No outcome recorded |
| Phase 1 | NCT00548678 Comparator | Oct → Nov 2007 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02251795 Background | Aug 2007 → Jun 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00258245 Background | May 2005 → Apr 2008 | plasma cell myeloma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02273544 Background | Sep → Oct 2002 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02226926 Comparator | Jul → Sep 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273505 Comparator | Apr → May 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT03176498 Background | Dec 2026 → Jun 2027 | cerebral infarction | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT06826859 Comparator | Jun 2025 → Jul 2029 expected | preeclampsia | Thomas Jefferson University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06660498 Comparator | May 2025 → Mar 2027 expected | HIV infectious disease | University of Aarhus | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03533153 Background | Mar 2021 → Dec 2023 | myocardial infarction | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/2 | NCT04168398 Background | Jul 2019 → Nov 2021 | limb ischemia | Mansoura University | Completed | No outcome recorded |
| Phase 1/2 | NCT04434365 Background | Jun → Nov 2019 | coronary artery disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03787927 Background | Dec 2018 → Dec 2021 | blood platelet disease, hemorrhagic disease, platelet disorder, undefined | Bloodworks | Unknown | No outcome recorded |
| Phase 1/2 | NCT03318484 Background | Nov 2017 → Nov 2019 | atherosclerosis, peripheral arterial disease | First Affiliated Hospital of Harbin Medical University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02834403 Background | Nov 2016 → Jan 2021 | triple-negative breast carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01355705 Background | Aug 2011 → Jul 2016 | plasma cell myeloma | Michaela Liedtke | Completed | No outcome recorded |
| Phase 1/2 | NCT00790842 Background | Jan 2009 → Sep 2017 | plasma cell myeloma | PrECOG, LLC. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00833833 Background | Jun 2008 → Apr 2011 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 283 trials | ||||||
| Phase 2 | NCT07032389 Background | Dec 2025 → Jun 2030 expected | acute coronary syndrome | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06638151 Comparator | Sep 2025 → Jul 2026 | ischemic stroke | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT06935994 Comparator | May 2025 → Dec 2028 expected | metabolic dysfunction-associated steatotic liver disease | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06601127 Background | Feb 2025 → Apr 2026 overdue | ischemic stroke | Tianjin Institute of Pharmaceutical Research Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06478537 Background | Jun 2024 → Jun 2027 expected | thrombocytopenia due to immune destruction | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07292259 Background | Jan 2024 → Dec 2025 | beta-thalassemia major | Pakistan Blood and Marrow Transplant (PBMT) Group | Completed | No outcome recorded |
| Phase 2 | NCT06315530 Background | Dec 2023 → Apr 2025 | primary antiphospholipid syndrome | Ruijin Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05411718 Comparator | Mar 2023 → Nov 2026 expected | Lynch syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05035316 Comparator | Jan 2022 → Nov 2024 | bipolar disorder | Lars Vedel Kessing | Completed | No outcome recorded |
| Phase 2 | NCT04937088 Comparator | Dec 2021 → Dec 2022 | COVID-19 | Louisiana State University Health Sciences Center in New Orleans | Unknown | No outcome recorded |
| Phase 2 | NCT04516993 Background | Sep 2021 → Sep 2023 | stroke disorder | Huashan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05233124 Comparator | Sep 2021 → Jun 2023 | acute coronary syndrome, vascular ectasia | Instituto Nacional de Cardiologia Ignacio Chavez | Unknown | No outcome recorded |
| Phase 2 | NCT04243122 Comparator | Feb 2021 → Oct 2023 | acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis, venous thromboembolism | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT04181749 Comparator | Nov 2020 → Jan 2024 | — | University of Leicester | Unknown | No outcome recorded |
| Phase 2 | NCT04239196 Background | Sep → Nov 2020 | anterior ischemic optic neuropathy, temporal arteritis | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | Unknown | No outcome recorded |
| Phase 2 | NCT04219774 Comparator | May 2020 → Mar 2024 | carotid artery occlusion, cognitive disorder, stroke disorder | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04368377 Background | Apr 2020 | COVID-19, respiratory failure, thrombotic disease, viral pneumonia | University of Milan | Completed | No outcome recorded |
| Phase 2 | NCT04160546 Background | Jan 2020 → Dec 2025 overdue | chronic myeloid leukemia | CRIS Cancer Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04182100 Background | Dec 2019 → Mar 2021 | acquired polycythemia vera | PharmaEssentia Japan K.K. | Completed | No outcome recorded |
| Phase 2 | NCT04122170 Comparator | Sep 2019 → Sep 2021 | — | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03667326 Comparator | Jul 2019 → Jun 2026 overdue | preeclampsia | Columbia University | Recruiting | No outcome recorded |
| Phase 2 | NCT01784159 Comparator | Mar 2019 → Dec 2022 | infectious disease with sepsis | Federal University of São Paulo | Terminated | No outcome recorded |
| Phase 2 | NCT03766581 Background | Jan 2019 → Mar 2022 | transient ischemic attack | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT03152409 Comparator | Nov 2018 → Feb 2021 | major depressive disorder | Jessica Harder | Terminated | No outcome recorded |
| Phase 2 | NCT04031859 Background | Oct 2018 → Jul 2019 | — | Ministry of Health, Saudi Arabia | Completed | No outcome recorded |
| Phase 2 | NCT03480776 Comparator | Jul 2018 → Jun 2026 overdue | ovarian carcinoma | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02838030 Background | Jul 2018 → Jul 2021 | — | University of Guadalajara | Suspended | No outcome recorded |
| Phase 2 | NCT03192059 Background | Jul 2017 → Jun 2021 | cervical cancer, endometrial cancer | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 2 | NCT02998905 Comparator | Apr 2017 → Oct 2019 | atrial fibrillation, intracerebral hemorrhage | Population Health Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03316534 Comparator | Jan → Apr 2017 | — | Azienda Ospedaliera di Perugia | Completed | No outcome recorded |
| Phase 2 | NCT03008915 Comparator | Jan 2017 → Jul 2018 | alpha 1-antitrypsin deficiency, pulmonary emphysema | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02677545 Background | Dec 2016 → Apr 2022 | carotid stenosis | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2 | NCT02671461 Background | Apr 2016 → Mar 2017 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02678221 Background | Feb 2016 → Feb 2017 | fetal growth restriction | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT03038607 Comparator | Jan 2016 → Jan 2017 | selective intrauterine growth restriction | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02578706 Comparator | Oct 2015 → Nov 2016 | HIV infectious disease | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02519608 Background | Sep 2015 → Jun 2016 | chronic obstructive pulmonary disease, coronary artery disorder | University Hospital of Ferrara | Completed | No outcome recorded |
| Phase 2 | NCT02531451 Comparator | Sep 2015 → Jun 2016 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT02293395 Comparator | Apr 2015 → Oct 2016 | acute coronary syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02696577 Comparator | Mar 2015 → Jan 2016 | fetal growth restriction | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02559414 Comparator | Feb 2015 → Apr 2016 | HIV infectious disease, cardiovascular disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT02295826 Comparator | Jan 2015 → Dec 2018 | transient ischemic attack | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT02323516 Comparator | Dec 2014 → Dec 2015 | cancer | Centre Francois Baclesse | Withdrawn | No outcome recorded |
| Phase 2 | NCT02280031 Comparator | Nov 2014 → Oct 2016 | fetal growth restriction, preeclampsia | CHU de Quebec-Universite Laval | Completed | No outcome recorded |
| Phase 2 | NCT02271399 Comparator | Oct 2014 → Jan 2016 | venous thromboembolism | Hanyang University Seoul Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02260622 Comparator | Oct 2014 → Jun 2017 | limb ischemia | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02155985 Comparator | Aug 2014 → Jun 2015 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02176655 Comparator | Jul 2014 → Jan 2016 | alcohol-induced mental disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT02081638 Comparator | Apr 2014 → Oct 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01902498 Comparator | Jul 2013 → Mar 2014 | postoperative ventricular dysfunction | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01802775 Background | Feb 2013 → Dec 2014 | peripheral arterial disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01800357 Background | Jan 2013 → Jun 2014 | ischemic stroke | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01797575 Comparator | Jan 2013 → Feb 2017 | bipolar disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT01646814 Comparator | Sep 2012 → Jun 2013 | peptic ulcer disease | PLx Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01659307 Comparator | Sep 2012 → Sep 2022 | acute lung injury | Belfast Health and Social Care Trust | Completed | No outcome recorded |
| Phase 2 | NCT01426438 Background | Nov 2011 → Oct 2013 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01466452 Comparator | Sep 2011 → Sep 2013 | coronary atherosclerosis | Centro Cardiologico Monzino | Unknown | No outcome recorded |
| Phase 2 | NCT01259817 Comparator | Sep 2011 → Dec 2016 | acquired polycythemia vera, essential thrombocythemia | Ronald Hoffman | Completed | No outcome recorded |
| Phase 2 | NCT01328145 Comparator | Apr 2011 → Dec 2012 | chronic obstructive pulmonary disease | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT01362218 Comparator | Oct 2010 → Apr 2012 | low density lipoprotein cholesterol, mild elevation of | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT02120092 Comparator | Oct 2010 → Dec 2013 | acute coronary syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT01114048 Background | Mar 2010 → Mar 2012 | plasma cell myeloma | Chonnam National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00940784 Background | Jun 2009 → Jan 2011 | acquired polycythemia vera | Ronald Hoffman | Withdrawn | No outcome recorded |
| Phase 2 | NCT01976806 Background | Jun 2009 → Sep 2011 | gingivitis, periodontitis | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00790452 Comparator | Nov 2008 → Oct 2009 | glioblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00783614 Comparator | Oct 2008 → Jan 2010 | HIV infectious disease | Hennepin Healthcare Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00691704 Background | Aug 2008 → Dec 2012 | plasma cell myeloma | Cristina Gasparetto | Completed | No outcome recorded |
| Phase 2 | NCT00789308 Background | Jul 2008 → Jul 2013 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01831011 Background | Jul 2008 → Apr 2010 | ischemic stroke | Xijing Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00642811 Background | May 2008 → Mar 2009 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00528411 Background | Oct 2007 → Mar 2009 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00482261 Background | Jun 2007 → Aug 2010 | plasma cell myeloma | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 2 | NCT01103440 Background | Apr 2007 → Jun 2009 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT00684203 Background | Dec 2006 → Oct 2007 | atherosclerosis, myocardial infarction, myocardial ischemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00684515 Background | Sep 2006 → Nov 2007 | cerebral infarction | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00384865 Comparator | Sep 2006 → Oct 2009 | pulmonary arterial hypertension | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2 | NCT01051778 Background | Jun 2006 → Nov 2009 | habitual spontaneous abortion | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT00300365 Background | Nov 2005 → Aug 2010 | metabolic syndrome X | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00368238 Background | Oct 2005 → Jul 2006 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT00062023 Comparator | Jun 2003 → Apr 2005 | colorectal cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00061373 Background | May 2003 → Dec 2009 | ischemic stroke | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00000469 Background | May 1988 → Aug 1998 | carotid stenosis, cerebral atherosclerosis, heart disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00000520 Background | Jul 1985 → Nov 1989 | Kawasaki disease, coronary aneurysm | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2/326 trials | ||||||
| Phase 2/3 | NCT07686770 Background | Aug 2026 → Sep 2027 expected | Kawasaki disease | Children's Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06653348 Background | Apr 2024 → Jul 2026 overdue | transient ischemic attack | Mazandaran University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06238115 Background | Mar 2024 → Oct 2025 | intracranial berry aneurysm, thrombotic disease | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05700266 Background | Dec 2023 → Dec 2024 | intracranial arteriosclerosis, ischemic stroke | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05515120 Comparator | Jan 2021 → Jan 2022 | bleeding disorder, vascular-type, pulmonary embolism, venous thromboembolism | Mexican Social Security Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT05531942 Comparator | Jan 2021 → Oct 2023 | ischemic stroke | Shanghai Yueyang Integrated Medicine Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05663307 Comparator | Jan 2021 → Nov 2023 | ischemic stroke | Shanghai Yueyang Integrated Medicine Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 2/3 | NCT04425590 Background | Apr → Aug 2020 | ischemic stroke | Duta Wacana Christian University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03503227 Comparator | Apr → Oct 2018 | female infertility | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03273322 Comparator | Sep 2017 → Nov 2018 | atrial fibrillation, hemorrhagic disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT03219645 Comparator | Jul → Oct 2017 | ischemic stroke | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02976701 Background | Nov 2016 → Jan 2023 | ST-elevation myocardial infarction | Dexa Medica Group | Terminated | No outcome recorded |
| Phase 2/3 | NCT02929888 Comparator | Oct 2016 → Jul 2017 | acute myocardial infarction | Fundacion Investigacion Interhospitalaria Cardiovascular | Unknown | No outcome recorded |
| Phase 2/3 | NCT02506140 Background | Aug 2015 → Mar 2017 | transient ischemic attack | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02387086 Background | May 2015 → May 2017 | non-small cell lung carcinoma | Bai Jun | Unknown | No outcome recorded |
| Phase 2/3 | NCT02878772 Comparator | May 2014 → Dec 2015 | ischemic stroke | Tianjin Medical University General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01924325 Comparator | Jan 2014 → Dec 2015 | transient ischemic attack | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02221102 Comparator | Dec 2013 → Jun 2015 | cerebral infarction, ischemic disease | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01923818 Comparator | Sep 2013 → Sep 2015 | transient ischemic attack | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01635426 Comparator | Mar 2012 → Jan 2018 | pregnancy loss, recurrent, 4 | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01211925 Comparator | Sep 2009 → Jul 2010 | limb ischemia | Clinical Centre of Serbia | Unknown | No outcome recorded |
| Phase 2/3 | NCT01231165 Comparator | Feb 2009 → May 2010 | coronary artery disorder | University of Carabobo | Completed | No outcome recorded |
| Phase 2/3 | NCT00816166 Comparator | Oct 2008 → Apr 2013 | transient ischemic attack | Codman & Shurtleff | Terminated | No outcome recorded |
| Phase 2/3 | NCT01586975 Comparator | Jul 2007 → Apr 2010 | ischemic stroke, myocardial infarction | Northwestern University | Completed | No outcome recorded |
| Phase 2/3 | NCT00109382 Background | May 2003 → Feb 2007 | transient ischemic attack | University of Calgary | Completed | No outcome recorded |
| Phase 3150 trials | ||||||
| Phase 3 | NCT07572747 Comparator | Apr 2027 → Apr 2032 expected | coronary artery disorder | Khalid F Alhabib | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07379190 Background | Jun 2026 → Feb 2029 expected | cerebral infarction | Weifang Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT07529262 Comparator | Jun 2026 → Jun 2030 expected | cirrhosis of liver | Curtin University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07658807 Background | Jun 2026 → Feb 2028 expected | arterial occlusion, diabetic peripheral angiopathy, peripheral arterial disease | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07540416 Comparator | May 2026 → Dec 2027 expected | ischemic stroke | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Show all 150 trials opens the full record — a long page | ||||||
| Phase 4278 trials | ||||||
| Phase 4 | NCT07684742 Comparator | Jul 2026 → Jul 2031 expected | ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome | Gyeongsang National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644247 Comparator | Jun 2026 → Jan 2029 expected | hemorrhagic disease, left ventricular failure, stroke disorder, thrombotic disease | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07609654 Comparator | Jun 2026 → Jun 2029 expected | atrial fibrillation, intracerebral hemorrhage, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05225961 Comparator | Mar 2026 | ischemic stroke | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| Phase 4 | NCT07511257 Comparator | Feb 2026 → Jun 2029 expected | ST-elevation myocardial infarction, acute coronary syndrome, vascular ectasia | Instituto Nacional de Cardiologia Ignacio Chavez | Recruiting | No outcome recorded |
| Show all 278 trials opens the full record — a long page | ||||||
| Phase not applicable128 trials | ||||||
| — | NCT07699003 Background | Aug 2026 → Aug 2029 expected | cerebral artery occlusion | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT06981390 Comparator | May 2026 → Feb 2027 expected | coronary artery disorder | Kexiang Liu, MD | Not yet recruiting | No outcome recorded |
| — | NCT05650411 Comparator | Apr 2026 → May 2028 expected | coronary stenosis | IGLESIAS Juan Fernando | Recruiting | No outcome recorded |
| — | NCT07495969 Background | Apr 2026 → Dec 2027 expected | cerebral artery occlusion, ischemic stroke | Feng Gao | Not yet recruiting | No outcome recorded |
| — | NCT06714526 Background | Oct 2025 → Aug 2027 expected | cerebral atherosclerosis | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Show all 128 trials opens the full record — a long page | ||||||
| Phase not stated1 trial | ||||||
| — | NCT01049633 Background | — | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | No longer available | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-05-22 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin Combination Tablets"® otsuka.co.jp ↗ |
| 2020-03-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Cabpirin Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin® otsuka.co.jp ↗ |
| 2012-06-22 | Daiichi Sankyo | NEXIUM receives approval in Japan for prevention of recurrence of gastric ulcer and duodenal ulcer in patients treated with aspirin at low doses daiichisankyo.com ↗ |
Evidence & citations 78 cited values
Every value below carries the sentence it was read from. 1,352 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aspirin | “patients aged 18 years or older with an acute coronary syndrome who completed the IVUS-ACS study and who had no major ischaemic or bleeding events after 1-month treatment with...” PMID 38599220 ↗ Apr 20241133“The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and...” NCT07658989 ↗ “Thromboprophylactic regimens Aspirin®(acetylsalicylic acid, AA, Bayer) 300mg/day or Xarelto® (rivaroxaban, factor Xa-inhibitor, Bayer) 10mg/day will be randomly(according to...” NCT02271399 ↗ “This is a research study to compare the efficacy of aspirin (acetylsalicylic acid) and pneumatic compression devices versus enoxaparin (also known as Lovenox) and pneumatic...” NCT01696760 ↗ “Eligible patients, who have a history or new onset paroxysmal, persistent, or permanent non-valvular AF, referred to the study centers with indications for PCI will be randomly...” PMID 26003433 ↗ May 2015 “Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary...” NCT02548650 ↗ “A total of 2268 STEMI patients indicated for primary PCI with current generation platinum‑chromium everolimus-eluting stents were randomized 1:1 to either prasugrel monotherapy...” PMID 41436299 ↗ Dec 2025 “Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors...” NCT03703635 ↗ “The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has...” NCT06535568 ↗ “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Participants were randomly assigned (1:1) to receive DAPT (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily) for 12 months or the same dual antiplatelet regimen for...” PMID 42120081 ↗ May 2026 “Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of...” NCT06774846 ↗ “The objective of this study is to investigate whether intravenous administration (injected into a vein) of acetylsalicylic acid (Aspirin) in doses of 250 and 500 mg is superior...” NCT00910065 ↗ “Patients may be prescribed single antiplatelet therapy (e.g., aspirin or clopidogrel) or no antithrombotic therapy, strictly at the discretion of the treating physician based...” NCT07609654 ↗ “dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet...” NCT02762864 ↗ “All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if...” NCT01208714 ↗ “De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg...” NCT04755387 ↗ “Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on...” NCT03287167 ↗ “Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis...” NCT06954155 ↗ “Patients in the AT group will receive aspirin plus clopidogrel for 1 year, while patients in the ATW group receive aspirin plus clopidogrel for 1 year with extra warfarin...” PMID 41213699 ↗ Nov 2025 “Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was...” NCT05623904 ↗ “We performed a randomized, double-blind, placebo-controlled trial to determine whether a combination of acetylsalicylic acid (aspirin), calcitriol, and calcium carbonate could...” PMID 26404953 ↗ Sep 2015 “Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT04948749 ↗ “Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT05980195 ↗ “6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the...” NCT05650411 ↗ “Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months...” NCT02303717 ↗ “The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the...” NCT01396395 ↗ “The subjects are randomized into study group and control group using central randomization for open-label dosing:(1) Study group: dabigatran etexilate 110 mg bid + aspirin 100...” NCT03536611 ↗ “Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy...” NCT05387954 ↗ “Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months...” NCT04708587 ↗ “Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with...” NCT01261832 ↗ “Initiate dual antiplatelet therapy as early as possible (aspirin 100 mg/day plus clopidogrel 75 mg/day) for a total of 21 days, followed by long-term maintenance with aspirin...” NCT07379190 ↗ “In the standard dual antiplatelet therapy (Standard DAPT) group, aspirin 100 mg once daily will be administered in combination with prasugrel 10 mg once daily or ticagrelor 90...” NCT07684742 ↗ “SAPT arm will continue to receive 45 days of OAC monotherapy followed by low-dose aspirin (75～100 mg/day) as an antithrombotic agent required through the end of the study...” NCT07125417 ↗ “Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first...” NCT04995159 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01326676 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01057537 ↗ “Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin in Korean Patients With Coronary Artery Disease (a Single-center, Randomized, Open-label Clinical Trial)” NCT01763749 ↗ “Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.” NCT03797651 ↗ “All the patients received once-daily oral rivaroxaban (10 mg) until postoperative day 5 and then were randomly assigned to continue rivaroxaban or switch to aspirin (81 mg daily)” PMID 29466159 ↗ Feb 2018 “Standard of Care (SoC) TB treatment + acetylsalicylic acid 300mg twice daily during first 4 weeks of TB treatment followed by aspirin 300mg once daily for an additional 4 weeks.” NCT04575519 ↗ “Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug.” NCT03900871 ↗ “Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.” NCT02976701 ↗ “Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance.” NCT06899399 ↗ “Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 months of DAPT with aspirin and clopidogrel (n = 2091).” PMID 35234821 ↗ Apr 2022 “From the 1st to the 21st day, the patient should receive dual anti - platelet therapy with clopidogrel 75mg once a day (qd) combined with aspirin 100mg once a day (qd).” NCT06853535 ↗ “Participants will receive Aspirin or continue an equivalent NSAID as part of the OAT ICI protocol while receiving standard-of-care immune checkpoint inhibitor therapy.” NCT07661459 ↗ “dabigatran 110mg twice daily or 150mg twice daily+ aspirin 100mg once daily / clopidogrel 75mg once daily / ticagrelor 90mg twice daily / cilostazol 100mg twice daily” NCT06058130 ↗ “This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.” NCT05063630 ↗ “Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.” NCT05622500 ↗ “Aspirin 100mg/day plus cilostazol 200 mg/day is given to the 100 patients in one group, and aspirin 100 mg/day alone is given to 100 patients in another group.” NCT00333164 ↗ “Patients in Low-dose Tiprogrel group and High-dose Tiprogrel group will accept long term dual antiplatelet therapy (DAPT) (Aspirin and Tiprogrel for 90 days) .” NCT06601127 ↗ “Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522).” PMID 31237644 ↗ Jun 2019 “BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks” NCT03638297 ↗ “Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol.” NCT00963781 ↗ “The polypill will consist of a high-intensity statin (rosuvastatin 40 mg daily), aspirin 81 mg daily, and either clopidogrel 75 mg or prasugrel 10 mg daily.” NCT05514938 ↗ “we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily.” PMID 18753638 ↗ Aug 2008 “The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.” NCT02800174 ↗ “Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily” NCT01012193 ↗ “Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.” NCT02398656 ↗ “The polypill combines DAPT and a high intensity statin: (a) aspirin 81 mg, (b) rosuvastatin (40 or 10 mg) and (c) prasugrel 10 mg or clopidogrel 75 mg.” NCT07032389 ↗ “A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily” NCT01271985 ↗ “Aspirin 100 mg orally once daily + Clopidogrel 75 mg orally once daily, or Aspirin 100 mg + Ticagrelor 90 mg orally twice daily, continued for 21 days” NCT07476898 ↗ “Aspirin 100 mg and Clopidogrel 75 mg daily for 1 month, followed by single antiplatelet therapy (Aspirin 100 mg or Clopidogrel 75 mg) up to 12 months.” NCT07592507 ↗ “Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.” NCT01212302 ↗ “Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated” NCT01953874 ↗ “For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day” NCT03552354 ↗ “Doses are aspirin either 81mg or loading dose 325mg, clopidogrel either 75mg or loading dose 300mg, ticagrelor either 90mg or loading dose 180mg.” NCT06943586 ↗ “Patients receive aspirin and clopidogrel for 1 month after PCI. After 1 month, aspirin is discontinued and clopidogrel monotherapy is continued.” NCT07198529 ↗ “This micro-clotting cascade supports the potential role of anticoagulants like aspirin, heparin in the clinical management of COVID-19 patients.” NCT04768179 ↗ “Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）” NCT03102502 ↗ “25 mg aspirin plus 200 mg extended-release dipyridamole open-label twice daily or 100 mg aspirin monotherapy open-label once daily for 7 days.” PMID 20060783 ↗ Jan 2010 “100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)” NCT00984113 ↗ “Participants that are carriers of the CYP2C19 gene will receive either Ticagrelor monotherapy, or dual therapy with Ticagrelor and Aspirin.” NCT07602257 ↗ “The trial compared a Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide) to Standard Practice.” PMID 21205325 ↗ Jan 2011 “Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation” NCT05770674 ↗ “A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol.” NCT05963568 ↗ “Subjects must be treated with aspirin for the duration of the trial. The minimum daily maintenance dose of aspirin should be 75-100 mg.” NCT02605447 ↗ “Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months” NCT04128956 ↗ “The polypill comprises hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg.” PMID 32894967 ↗ Aug 2020 “Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.” NCT03219645 ↗ “All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study” NCT02330640 ↗ “A capsule of Polycap contained aspirin 100 mg, simvastatin 20 mg, hydrochlorothiazide 12.5 mg, ramipril 5 mg, and atenolol 50 mg.” PMID 39082406 ↗ Jul 2024 “Aspirin: Peroral (PO) tablet with standard dosages of 325 mg, 500 mg, and 400 mg effervescent; treatment dosage of up to 1000 mg” NCT07127107 ↗ “antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs” NCT04581759 ↗ “Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (clopidogrel) and aspirin (81 mg or more/day).” NCT07076082 ↗ “Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.” NCT03947229 ↗ “NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months” NCT04323280 ↗ “Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;” NCT06316570 ↗ “This study assesses potential effects of low-dose aspirin (100 mg daily) on pregnancy rate following frozen embryo transfer.” NCT01633528 ↗ “Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily” NCT00603590 ↗ “Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.)” NCT01502943 ↗ “Aspirin and clopidogrel are Class A recommended drugs for the prevention and treatment of non cardiac cerebral infarction.” NCT06269432 ↗ “Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.” NCT01974544 ↗ “Cilostazol seems to be non-inferior, and might be superior, to aspirin for prevention of stroke after an ischaemic stroke.” PMID 20833591 ↗ Sep 2010 “These data demonstrate that PL-ASA may be co-administered with food without significant impact on aspirin bioavailability.” PMID 32080811 ↗ Apr 2020 “Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice” NCT02843633 ↗ “Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy.” NCT04976465 ↗ “High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily” NCT05936606 ↗ “Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily.” NCT05902000 ↗ “aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days” NCT07195812 ↗ “Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.” NCT05974033 ↗ “1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)” NCT05066789 ↗ “associated with low-dose aspirin of 100 mg/day except for patients already receiving anticoagulant therapy” NCT06965244 ↗ “Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease” NCT04950790 ↗ “Aspirin 100 mg and clopidogrel 300 mg are administered within 6 ± 2 hours following thrombolytic therapy” NCT06414499 ↗ “fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)” NCT03541109 ↗ “low-dose aspirin (acetylsalicylic acid, ASA) daily from the first trimester until 36 weeks of gestation” NCT07665853 ↗ “Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd” NCT06283888 ↗ “Group 2: Aspirin 80-100 mg/day + clopidogrelª 75 mg/day followed by aspirin 80-100 mg/day for 9 months#” NCT05632445 ↗ “SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.” NCT06315530 ↗ “Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease.” NCT00966485 ↗ “1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy” NCT04609111 ↗ “All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1.” PMID 23803136 ↗ Jun 2013 “Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion.” NCT00790842 ↗ “All eligible STEMI patients will be received standard DAPT (ticagrelor or clopidogrel plus aspirin).” NCT06013020 ↗ “PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole” NCT00960869 ↗ “Aspirin (150-300mg) is offered to patients allocated in the control arm, unless contraindicated.” NCT05752916 ↗ “Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.” NCT03318484 ↗ “Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.” NCT01686230 ↗ “dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion” NCT05567562 ↗ “Antiplatelet therapy with aspirin (100 mg) and/or clopidogrel (75 mg) will be administered” NCT07347626 ↗ “medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days” NCT01763320 ↗ “FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril” NCT01321255 ↗ “Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.” NCT06015477 ↗ “30-day dual antiplatelet therapy (DAPT; aspirin plus P2Y12 inhibitor) strategy post-PCI” PMID 39007830 ↗ Jul 2024 “standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.” NCT06216821 ↗ “Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.” NCT05141305 ↗ “Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures” NCT02227368 ↗ “an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin” NCT06591312 ↗ “aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)” NCT05077683 ↗ “Patients started taking aspirin (at a dose of 200 mg) or placebo just before surgery” PMID 24679062 ↗ Mar 2014 “Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d” NCT00166257 ↗ “polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg” NCT01313702 ↗ “early escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin <6 months)” PMID 40886179 ↗ May 2026 “Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)” NCT04703608 ↗ “medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated” NCT05479097 ↗ “Subjects will receive 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis.” NCT00691704 ↗ “most prominently acetylsalicylic acid (ASA, aspirin) for a cardiac indication.” NCT05637567 ↗ “dual antiplatelet (aspirin 100 mg + clopidogrel 75 mg daily) for first 90 days” NCT07699003 ↗ “PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)” PMID 26725920 ↗ Apr 2016 “Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis” NCT05894954 ↗ “Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)” NCT04045665 ↗ “including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d)” NCT03533153 ↗ “but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.” NCT03718559 ↗ “7. Aspirin 81 once per day from postoperative day 1 to postoperative day 30.” NCT06561035 ↗ “Single APT with either aspirin or clopidogrel is discontinued in this arm.” NCT01962545 ↗ “100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month” NCT01267734 ↗ “Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)” NCT05627375 ↗ “ARM I: Patients receive oral acetylsalicylic acid (aspirin) once daily.” NCT00468910 ↗ “Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.” NCT05531942 ↗ “Aspirin + clopidogrel for 3-months schedule after the coronary stenting” NCT02609698 ↗ “Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks” NCT04135677 ↗ “Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone” NCT07047014 ↗ “without interruption of either aspirin and/or P2Y12 receptor inhibitor” NCT03218787 ↗ “Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.” NCT02596126 ↗ “Dual antiplatelet therapy with aspirin 200mg and clopidogrel 300mg.” NCT07111559 ↗ “P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure” NCT04753749 ↗ “asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily” NCT01011257 ↗ “antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day)” NCT00691314 ↗ “Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)” NCT07095790 ↗ “Single antiplatelet therapy such as aspirin or a P2Y12 inhibitor.” NCT07496281 ↗ “To prevent thrombosis, aspirin (2-4 mg/kg per day) will be used.” NCT07292259 ↗ “* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month” NCT01354808 ↗ “Proprietary oral formulation of 486mg aspirin and 80mg ketamine” NCT05615948 ↗ “Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.” NCT04168398 ↗ “A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin” NCT01388660 ↗ “Arm 2: Treatment with liquid aspirin 150 mg daily. (ASA 150).” NCT04937088 ↗ “Acetylsalicylic acid (aspirin) 325 mg capsules three per day” NCT00587496 ↗ “aspirin 300mg/d for 1 month followed by 100mg/d chronically” NCT01371058 ↗ “aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol” NCT03062319 ↗ “Subjects will be treated with Aspirin and P2Y12 inhibitor.” NCT02118870 ↗ “Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day.” NCT07088523 ↗ “Low-dose Aspirin: 75 mg orally, daily, until progression.” NCT06425133 ↗ “aspirin (325 mg daily) and/or warfarin (target INR = 2.5)” NCT00201461 ↗ “aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)” NCT03415386 ↗ “Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC” NCT05761704 ↗ “Aspirin and clopidogrel 30 days after DES implantation” NCT06339021 ↗ “100 mg aspirin per day throughout the follow-up period” NCT07495969 ↗ “Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)” NCT06655194 ↗ “* Month 0-1: Aspirin 100 mg qd + Ticagrelor 90 mg bid” NCT07432516 ↗ “Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo” NCT01453400 ↗ “Aspirin medication during thalidomide administration” NCT01114048 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain” NCT01361399 ↗ “Preloading with Aspirin and Clopidogrel before TAVI” NCT03001960 ↗ “Day 1: Aspirin 100-300mg/day + clopidogrel placebo” NCT03635749 ↗ “with accompanied aspirin and clopidogrel treatment” NCT01163604 ↗ “aspirin enteric-coated tablets (0.1 g once daily)” NCT07074834 ↗ “Aspirin, clopidogrel or other antiplatelet drugs.” NCT04491695 ↗ “P2Y12 inhibitors and Aspirin (ASA) up to 90 days” NCT03008083 ↗ “Acetylsalicylic acid (ASA)/aspirin 200 mg daily” NCT02607072 ↗ “500 mg acetylsalicylic acid (Aspirin, BAYE4465)” NCT03225352 ↗ “75 mg once daily in combination with aspirin” NCT00243178 ↗ “Ticagrelor 90 mg plus aspirin for 12 months” NCT04060914 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT01072604 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT01552798 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT02313909 ↗ “low-dose aspirin (81 mg once daily orally)” NCT02144064 ↗ “Acetylsalicylic Acid (Aspirin BAY1019036)” NCT01081353 ↗ “Acetylsalicylic acid - (Aspirin - Bayer)” NCT01012349 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01465009 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01464983 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT01028079 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01464944 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT01062360 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT00963443 ↗ “Aspirin (100mg) plus cilostazol (200mg)” NCT00741286 ↗ “Aspirin 75 mg qd + Clopidogrel 75 mg qd” NCT03273322 ↗ “Including aspirin and clopidogrel, etc.” NCT03171597 ↗ “Including aspirin and clopidogrel, etc.” NCT03179618 ↗ “Including aspirin and clopidogrel, etc.” NCT03179514 ↗ “Aspirin maintenance dose (MD) = 81 mg.” NCT03606642 ↗ “Antiplatelet therapy (Aspirin therapy)” NCT02660866 ↗ “Including aspirin and clopidogrel, etc” NCT03179527 ↗ “Aspirin 100mg plus Sarpogrelate 100mg” NCT06424548 ↗ “aspirin 100 mg q.d. (Bayer, Germany)” NCT03234114 ↗ “Aspirin, clopidogrel, anticoagulant” NCT05507645 ↗ “Aspirin : D-1 300mg, D0-30 100mg qd” NCT01475552 ↗ “acetylsalicylic acid (ASA)-aspirin” NCT01994720 ↗ “Clopidogrel 75 mg +Aspirin 161 mg” NCT04393025 ↗ “aspirin 100mg or clopidogrel 75mg” NCT03073850 ↗ “aspirin (ASA) resistant patients” NCT01103440 ↗ “aspirin, clopidogrel, ticagrelor” NCT04012541 ↗ “received low dose aspirin only” NCT06565728 ↗ “stroke (aspirin, clopidogrel)” NCT02670161 ↗ “Aspirin 325mg PO or 650mg PR” NCT04261478 ↗ “Aspirin 250 mg, 81 mg, 75 mg” NCT07022496 ↗ “Aspirin 100 Mg oral Tablet” NCT04853719 ↗ “Aspirin and Clopidogrel” NCT03056118 ↗ “Aspirin with ticagrelor” NCT04989257 ↗ “give aspirin 200mg qd.” NCT05825391 ↗ “and aspirin 75 mg/day” NCT04239196 ↗ “Aspirin 81 mg q day” NCT00241904 ↗ “Aspirin, 75-100mg” NCT05375474 ↗ “aspirin 75 mg/d” NCT02539810 ↗ “Drug: Aspirin” NCT00799396 ↗ “Aspirin (ASA)” NCT01642238 ↗ “Aspirin 100mg” NCT05699070 ↗ “Drug: Aspirin” NCT02578706 ↗ “Drug: Aspirin” NCT04695106 ↗ “Drug: Aspirin” NCT07540416 ↗ “aspirin,” NCT02086019 ↗ “aspirin” NCT01276691 ↗ “Aspirin” NCT02810704 ↗ “Aspirin” NCT00738894 ↗ |
| Known as | acetylsalicyclic acid | “Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio)” NCT02239120 ↗ |
| Known as | acetylsalicylacid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05270434 ↗ |
| Known as | Acetylsalicylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01681615 ↗ |
| Known as | acetylsalicylic acid | “To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg...” NCT02262793 ↗242“The goal of this clinical trial is to compare the pharmacokinetics (PK) pharmacodynamics (PD), safety and tolerability of acetylsalicylic acid powder for oral inhalation...” NCT05625347 ↗ “An Open-label, Randomized, Single-center, 2-way Cross-over Interaction Study, Evaluating the Effect of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg on the Pharmacodynamics and...” NCT01210339 ↗ “This study aims to evaluate the benefits of Acetylsalicylic acid (ASA) as an add-on treatment to local non-steroidal anti-inflammatory drug for the management of thrombotic...” NCT07663825 ↗ “Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and...” NCT01005290 ↗ “We investigated whether low-dose acetylsalicylic acid (ASA, aspirin) administration prior to and during exposure to an experimental sleep restriction challenge affects cellular...” PMID 41686719 ↗ Feb 2026 “Intervention group will discontinuate of Acetyl Salicylic acid at 24-28 weeks of gestation while Control Group will continue Acetyl Salicylic acid 150 mg/day until 36 weeks of...” NCT07665853 ↗ “Using the minimisation method in an online randomisation system, patients were randomly assigned (1:1) to receive 100 mg acetylsalicylic acid once per day in either the...” PMID 39577920 ↗ Dec 2024 “The present randomised controlled trial tests aspirin (acetylsalicylic acid (ASA)) as a convenient method to prevent overheating and improve exercise performance in persons with MS.” PMID 33191260 ↗ Nov 2020 “Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover” NCT02370680 ↗ “Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug.” NCT03900871 ↗ “Dual antiplatelet therapy of acetylsalicylic acid (ASA) with P2Y12 receptor antagonists such as clopidogrel is a cornerstone in the treatment of patients with advanced CAD.” NCT02080858 ↗ “Pregnant women at a higher risk for pre-eclampsia (PE) should be offered preventive daily treatment with acetylsalicylic acid (ASA) started before 16 weeks of gestation.” NCT03741179 ↗ “Compared with findings for plain aspirin and PL2200, this high rate of nonresponsiveness with EC aspirin was associated with lower exposure to acetylsalicylic acid” PMID 28089180 ↗ Jan 2017 “100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis” NCT02240953 ↗ “The purpose of this study was to compare the safety and efficacy of acetylsalicylic acid (ASA) and warfarin for thromboprophylaxis after the Fontan procedure.” PMID 21798429 ↗ Aug 2011 “Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.” NCT04182100 ↗ “Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.” NCT06002490 ↗ “One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.” NCT02176655 ↗ “who received ticagrelor and acetylsalicylic acid (ASA) in combination with dabigatran (150 mg bid), rivaroxaban (20 mg od) or phenprocoumon (INR 2.0-3.0).” PMID 25211369 ↗ Oct 2014 “Acetylsalicylic acid (aspirin) is an excellent candidate and is commonly used for secondary prevention of cardiovascular events in the general population” NCT00783614 ↗ “Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib.” NCT04160546 ↗ “At low doses, acetylsalicylic acid, or aspirin, has been proven to target the aforementioned angiogenic imbalance by decreasing serum sFlt-1 levels.” NCT05924971 ↗ “Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.” NCT01212302 ↗ “This is a study to compare the bioavailability of Acetyl Salicylic Acid (ASA) between Esomeprazole and Aspirin after multiple dose administration.” NCT01448031 ↗ “Treatment with a daily low dose of acetylsalicylic acid (aspirin 75 mg) is one of the cornerstones in management of CVD in non-diabetic patients” NCT01397513 ↗ “Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer.” PMID 31420787 ↗ Nov 2019 “Patients will receive clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.” NCT05773989 ↗ “Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg)” NCT01847404 ↗ “The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine.” NCT02735070 ↗ “Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months” NCT04128956 ↗ “Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill” NCT01506505 ↗ “Acetylsalicylic acid (1 study, 372 participants) may result in little to no difference in ipsilateral major or disabling stroke” PMID 37565307 ↗ Aug 2023 “Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)” NCT04575519 ↗ “Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.” NCT04184921 ↗ “Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.” NCT03543683 ↗ “Ticagrelor administered with Acetylsalicylic Acid (ASA) will provide better cerebral protection from microembolization” NCT02989558 ↗ “Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg)” NCT02791958 ↗ “Cyclooxygenase inhibitor acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy” NCT04962451 ↗ “Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg” NCT01245608 ↗ “An old investigation has shown that low-dose acetyl salicylic acid (ASA) treatment can remove this effect.” NCT04330729 ↗ “acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor” NCT05122780 ↗ “Acetylsalicylic acid was used as an antiplatelet agent (300 mg on days 1 and continuing with 100 mg/day).” NCT06102720 ↗ “low-dose aspirin (acetylsalicylic acid, ASA) daily from the first trimester until 36 weeks of gestation” NCT07665853 ↗ “Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease.” NCT00966485 ↗ “Aspirin (acetyl salicylic acid) remains for over 50 years the cornerstone of antiplatelet therapy” NCT02616497 ↗ “Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days.” NCT03005704 ↗ “Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.” NCT01741922 ↗ “clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months” NCT03284827 ↗ “Low-dose Aspirin (acetylsalicylic acid) has been shown to reduce the risk of preeclampsia” NCT07373756 ↗ “acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months” NCT02798913 ↗ “acetylsalicylic acid (ASA) and clopidogrel, a second-generation thienopyridine” NCT02120092 ↗ “Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.” NCT01227629 ↗ “Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily” NCT04619927 ↗ “Aspirin 150 mg / day (acetylsalicylic acid) once daily in the evening” NCT04356326 ↗ “the acetylsalicylic acid (ASA) is the most used antiaggregant product” NCT00425074 ↗ “DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month.” NCT05952206 ↗ “Aspirin (Acetylsalicylic Acid) (Bayer Corp, Morristown, NJ, USA)” PMID 23826440 ↗ Jun 2013 “oral acetylsalicylic acid (325 mg/ day for a total of 5 days)” NCT04192955 ↗ “Acetylsalicylic acid (aspirin) 325 mg capsules three per day” NCT00587496 ↗ “acetylsalicylic acid (aspirin), a cyclooxygenase inhibitor” PMID 24139424 ↗ Oct 2013 “acetylsalicylic acid powder for oral inhalation (i-ASA)” NCT05625334 ↗ “Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet” NCT00910065 ↗ “acetylsalicylic acid (ASA or aspirin) and clopidogrel” NCT02260622 ↗ “ticagrelor 180 mg and acetylsalicylic acid (ASA)” NCT01744288 ↗ “Low-dose aspirin (acetylsalicylic acid [ASA])” NCT06866964 ↗ “acetylsalicylic acid (aspirin, ASA; 325 mg)” PMID 22631032 ↗ Aug 2012 “acetylsalicylic acid (ASS Genericon) 500mg” NCT06710600 ↗ “Aspirin (Acetylsalicylic acid, BAYE4465)” NCT01033526 ↗ “Aspirin (Acetylsalicylic acid, BAYe4465)” NCT02394093 ↗ “Aspirin (Acetylsalicylic acid, BAYE4465)” NCT00501059 ↗ “Acetylsalicylic Acid (100 mg Oral q.d.)” NCT02239120 ↗ “25 mg Acetyl Salicylic Acid (Aggrenox®)” NCT02278302 ↗ “650 mg aspirin (Acetylsalicylic acid)” NCT05962034 ↗ “Drug: Aspirin (acetylsalicylic acid)” NCT01257893 ↗ “aspirin (acetylsalicylic acid [ASA])” NCT05525156 ↗ “Acetylsalicylic acid 100mg PO q24h” NCT05565976 ↗ “plus acetylsalicylic acid (ASA)” NCT00714961 ↗ “Aspirin - acetylsalicylic acid” NCT03103152 ↗ “acetylsalicylic acid (ASA)” NCT05262803 ↗ “acetylsalicylic acid (ASA)” NCT04284397 ↗ “Acetylsalicylic acid” NCT01638962 ↗ |
| Known as | Acetylsalicylic acid (ASA) | “Acetylsalicylic acid (ASA)” NCT04575519 ↗ |
| Known as | Albyl-E | “Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)” NCT00789308 ↗ |
| Known as | ASA | “To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg...” NCT02262793 ↗93“Study 2: subjects received clopidogrel alone (75 mg/day for 9 days) and clopidogrel alone for 4 days followed by clopidogrel plus fixed-combination esomeprazole 20 mg/low-dose...” PMID 24677117 ↗ Jun 2014 “This study aims to evaluate the benefits of Acetylsalicylic acid (ASA) as an add-on treatment to local non-steroidal anti-inflammatory drug for the management of thrombotic...” NCT07663825 ↗ “Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on...” NCT03287167 ↗ “We investigated whether low-dose acetylsalicylic acid (ASA, aspirin) administration prior to and during exposure to an experimental sleep restriction challenge affects cellular...” PMID 41686719 ↗ Feb 2026 “Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized...” NCT00496769 ↗ “However, single anti-platelet therapy with acetylsalicylic acid (ASA) without clopidogrel has been reported to improve bleeding outcomes and a composite of bleeding and...” NCT05035277 ↗ “The present randomised controlled trial tests aspirin (acetylsalicylic acid (ASA)) as a convenient method to prevent overheating and improve exercise performance in persons with MS.” PMID 33191260 ↗ Nov 2020 “Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3).” NCT00486512 ↗ “Fifty patients with T2D and carotid atherosclerotic plaques were randomly assigned to either a 200 mg/d cilostazol (CTZ) group or a 100 mg/d aspirin (ASA) group for 6 months.” PMID 32700396 ↗ Sep 2020 “Dual antiplatelet therapy of acetylsalicylic acid (ASA) with P2Y12 receptor antagonists such as clopidogrel is a cornerstone in the treatment of patients with advanced CAD.” NCT02080858 ↗ “Pregnant women at a higher risk for pre-eclampsia (PE) should be offered preventive daily treatment with acetylsalicylic acid (ASA) started before 16 weeks of gestation.” NCT03741179 ↗ “Previous data indicate that even at a dose of 20-30 mg/day, aspirin (ASA) allows almost complete inhibition of thromboxane (TX) A2 biosynthesis in healthy volunteers.” NCT06254391 ↗ “Comparative Pharmacokinetics of Asasantin Extended Release (ER) and of immediate release Persantin tablets combined with Acetyl salicylic acid (ASA) tablets” NCT02273505 ↗ “Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days.” NCT02189122 ↗ “Treatment with acetylsalicylic acid (ASA) following desensitization (ATAD) has been suggested as a therapeutic option in cases of severe CRSwNP with N-ERD.” PMID 40463360 ↗ May 2025 “who received ticagrelor and acetylsalicylic acid (ASA) in combination with dabigatran (150 mg bid), rivaroxaban (20 mg od) or phenprocoumon (INR 2.0-3.0).” PMID 25211369 ↗ Oct 2014 “Aspirin and Diabetes The efficacy and the safety of acetylsalicylic acid (aspirin, ASA) as an antithrombotic agent has been assessed in different subsets” NCT02895113 ↗ “Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib.” NCT04160546 ↗ “Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.” NCT01212302 ↗ “The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD)” NCT00189618 ↗ “This is a study to compare the bioavailability of Acetyl Salicylic Acid (ASA) between Esomeprazole and Aspirin after multiple dose administration.” NCT01448031 ↗ “Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer.” PMID 31420787 ↗ Nov 2019 “Acetylsalicylic acid (ASA) is one of the medications that can be used for the treatment of vascular injury present in systemic sclerosis” NCT03558854 ↗ “Aspirin (acetylsalicylic acid, ASA) has been selected, as it is shown to effectively reduce fatigue in prior non-exercise trials in MS” NCT03051646 ↗ “receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day” PMID 18757238 ↗ Aug 2008 “acetylsalicylic acid (ASA or Aspirin) may help reduce the abnormal platelet hyperactivity associated with blood clotting.” NCT05775965 ↗ “Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.” NCT04184921 ↗ “Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.” NCT03543683 ↗ “Ticagrelor administered with Acetylsalicylic Acid (ASA) will provide better cerebral protection from microembolization” NCT02989558 ↗ “Aspirin (ASA) has been shown to provide marked benefits in primary and secondary prevention of cardiovascular events.” NCT00725127 ↗ “Low dose aspirin (ASA) is currently the only prophylactic therapy known to decrease PEC in this patient population.” PMID 40633954 ↗ Jul 2025 “This study aims to determine the possible effects of Acetyl Salicylic Acid (ASA) and Terbutalin on ART treatment.” NCT00518141 ↗ “Cyclooxygenase inhibitor acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy” NCT04962451 ↗ “An old investigation has shown that low-dose acetyl salicylic acid (ASA) treatment can remove this effect.” NCT04330729 ↗ “low-dose aspirin (acetylsalicylic acid, ASA) daily from the first trimester until 36 weeks of gestation” NCT07665853 ↗ “Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin.” NCT00578760 ↗ “Aspirin (ASA) has been shown to provide marked benefits in the prevention of cardiovascular events” NCT00449618 ↗ “The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.” NCT00959621 ↗ “clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months” NCT03284827 ↗ “Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio)” NCT02239120 ↗ “BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)” NCT02671461 ↗ “acetylsalicylic acid (ASA) and clopidogrel, a second-generation thienopyridine” NCT02120092 ↗ “most prominently acetylsalicylic acid (ASA, aspirin) for a cardiac indication.” NCT05637567 ↗ “anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)” NCT02144831 ↗ “Aspirin (ASA) is a readily available and affordable antiplatelet medication” NCT04269863 ↗ “Long-term aspirin (ASA) is the standard recommended antithrombotic therapy” NCT04217447 ↗ “Aspirin (ASA), an NSAID, is a well-known antipyretic and analgesic agent” NCT05865548 ↗ “Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.” NCT01227629 ↗ “The acetylsalicylic acid (ASA) is the most used antiaggregant substance” NCT00501254 ↗ “Acetylsalicylic acid (ASA) is a well-known and safe anti-inflammatory.” PMID 34868050 ↗ Nov 2021 “the acetylsalicylic acid (ASA) is the most used antiaggregant product” NCT00425074 ↗ “Acetylsalicylic acid (ASA) will be given orally at a dose of 324 mg” NCT04192955 ↗ “Arm I: Chemoprevention. Enteric-coated Aspirin, ASA, NSC-27223.” NCT00002527 ↗ “Arm 2: Treatment with liquid aspirin 150 mg daily. (ASA 150).” NCT04937088 ↗ “DAPT using low-dose ASA (75-100mg) and clopidogrel (75mg)” NCT05632445 ↗ “Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose” NCT04121611 ↗ “acetylsalicylic acid (ASA or aspirin) and clopidogrel” NCT02260622 ↗ “Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)” NCT02396732 ↗ “with clopidogrel and aspirin (ASA) versus ASA alone” NCT03881943 ↗ “another treatment called Acetylsalicylic Acid (ASA)” NCT07213778 ↗ “Aspirin (ASA) Therapy and Preeclampsia Prevention” NCT04158830 ↗ “P2Y12 inhibitors and Aspirin (ASA) up to 90 days” NCT03008083 ↗ “ticagrelor 180 mg and acetylsalicylic acid (ASA)” NCT01744288 ↗ “Acetylsalicylic acid (ASA)/aspirin 200 mg daily” NCT02607072 ↗ “acetylsalicylic acid (ASA) therapy (81mg/day)” NCT02836652 ↗ “Low-dose aspirin (acetylsalicylic acid [ASA])” NCT06866964 ↗ “acetylsalicylic acid (aspirin, ASA; 325 mg)” PMID 22631032 ↗ Aug 2012 “acetylsalicylic acid (ASA, tablets, 100 mg)” NCT06400940 ↗ “Aspirin (ASA) daily during run-in (1 week)” NCT00626392 ↗ “Aspirin (ASA) Oral Tablet - Pre-Treatment” NCT04122170 ↗ “aspirin (acetylsalicylic acid [ASA])” NCT05525156 ↗ “aspirin (ASA) in healthy volunteers” PMID 36067089 ↗ Sep 2022 “500 mg Acetylsalicylic Acid (ASA)” NCT01062360 ↗ “Placebo and ASA (75 mg - 325 mg)” NCT01069003 ↗ “plus acetylsalicylic acid (ASA)” NCT00714961 ↗ “Acetylsalicylic acid (ASA)” NCT04575519 ↗ “acetylsalicylic acid (ASA)” NCT04284397 ↗ “Acetylsalicylic acid (ASA)” NCT02183220 ↗ “acetylsalicylic acid (ASA)” NCT02447809 ↗ “acetylsalicylic acid (ASA)” NCT04588727 ↗ “Acetylsalicylic acid (ASA)” NCT01994720 ↗ “Acetylsalicylic Acid (ASA)” NCT02556203 ↗ “acetylsalicylic acid (ASA)” NCT05262803 ↗ “Acetylsalicylic acid ASA” NCT01294462 ↗ “Acetylsalicylic acid ASA” NCT07683923 ↗ “Drug: Aspirin (ASA)” NCT01549418 ↗ “Daily aspirin (ASA)” NCT01066923 ↗ “Daily aspirin (ASA)” NCT06826859 ↗ “Aspirin (ASA)” NCT00122447 ↗ “Aspirin (ASA)” NCT04324463 ↗ “aspirin (ASA)” NCT01830543 ↗ |
| Known as | Ascriptin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | ASP | “Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy....” NCT04976465 ↗1“Aspirin (ASP), originally extracted from willow bark, is a small molecule compound with various effects such as antipyretic, anti-inflammatory, analgesic, and antiplatelet aggregation.” NCT06554535 ↗ |
| Known as | Aspegic | “Aspegic ® (Aspirin),100 mg/day” NCT00986765 ↗ |
| Known as | Aspir Low | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Aspir-Trin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Aspirin (ASA) | “Aspirin (ASA)” NCT01642238 ↗1“Aspirin (ASA)” NCT01823510 ↗ |
| Known as | Aspirin 325Mg Tab | “Aspirin 325Mg Tab, Aspirin 81Mg Tab” NCT05868525 ↗ |
| Known as | aspirin 81mg EC tab | “aspirin 81mg EC tab” NCT05567562 ↗ |
| Known as | Aspirin 81Mg Tab | “Aspirin 325Mg Tab, Aspirin 81Mg Tab” NCT05868525 ↗ |
| Known as | Aspirin cardio | “Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months” NCT04128956 ↗ |
| Known as | Aspirin Enteric-coated Tablets | “Aspirin Group: Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg...” NCT06738992 ↗5“Aspirin Enteric-coated Tablets, 0.1g/d by mouth” NCT03176498 ↗ “Drug: Aspirin Enteric-Coated Tablets” NCT07378228 ↗ |
| Known as | aspirin lysine | “Provided with supply of aspirin (aspirin lysine) for periods 1, 2 and 3 (2 boxes of 30 sachets)” NCT04990791 ↗ |
| Known as | Aspirin Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03130153 ↗ |
| Known as | Aspirin protect | “Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months” NCT04128956 ↗ |
| Known as | Aspirin Tablet | “Drug: Aspirin Tablet, 100 mg/d” NCT03186456 ↗ |
| Known as | Aspirin: acid acetylsalycilic | “Aspirin: acid acetylsalycilic” NCT00822536 ↗ |
| Known as | Aspirin: Aspirin Protect (Bayer) 100mg | “Aspirin: Aspirin Protect (Bayer) 100mg” NCT00947843 ↗ |
| Known as | Aspirin: Astrix | “Aspirin: Astrix” NCT01663038 ↗ |
| Known as | ASPIRINA | “A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered.” NCT05225961 ↗ |
| Known as | ASPIRINA JUNIOR | “A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)” NCT07444164 ↗ |
| Known as | Aspirtab | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Aspocid | “All patients will enroll to maximum doses guideline medical treatment that include (Beta blockers-Aspocid- Ator-Concor-Tritace).” NCT07045038 ↗ |
| Known as | Aspocid Paediatric | “Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))” NCT01051778 ↗ |
| Known as | Asprin | “Patient will receive dual anti platelet asprin And clopidogrel” NCT03896321 ↗ |
| Known as | Asprine | “preoperative gargling of Asprine and Benzydamine HCL to study comparative effects on intensity and duration of POST.” NCT05343429 ↗ |
| Known as | ASS Genericon | “acetylsalicylic acid (ASS Genericon) 500mg” NCT06710600 ↗ |
| Known as | Astrix | “versus co-administration of Plavix (clopidogrel) and Astrix (aspirin) in healthy male volunteers.” NCT01657071 ↗4“Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)” NCT01388660 ↗ “Plavix (clopidogrel) and Astrix (aspirin)” NCT01422109 ↗ “Aspirin: Astrix” NCT01496261 ↗ |
| Known as | Baby aspirin | “Baby aspirin 81mg: Twice daily for 6 weeks after surgery” NCT04766996 ↗ |
| Known as | Bay Aspirin | “Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily.” NCT05902000 ↗1“Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.” NCT03471169 ↗ |
| Known as | BAY e4465A | “A Prospective, Randomized, Verum Controlled, Open Label, Parallel Group Multi-center Phase III Clinical Trial to Demonstrate the Superiority of 500 or 250 mg Aspirin® i.v. (BAY...” NCT00910065 ↗ |
| Known as | BAY1019036 | “Acetylsalicylic acid (Fast release Aspirin, BAY1019036)” NCT01117636 ↗5“Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo” NCT01453400 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT01072604 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT01552798 ↗ “Acetylsalicylic acid (Aspirin, BAY1019036)” NCT02313909 ↗ “Acetylsalicylic Acid (Aspirin BAY1019036)” NCT01081353 ↗ |
| Known as | BAYE004465 | “Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)” NCT06655194 ↗ |
| Known as | BAYE4465 | “Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain” NCT01361399 ↗11“500 mg acetylsalicylic acid (Aspirin, BAYE4465)” NCT03225352 ↗ “Aspirin (Acetylsalicylic acid, BAYE4465)” NCT01033526 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01072604 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT01117636 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01465009 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01464983 ↗ “Acetylsalicylic acid (Aspirin, BAYE4465)” NCT01464944 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT01028079 ↗ “Aspirin (Acetylsalicylic acid, BAYe4465)” NCT02394093 ↗ “Acetylsalicylic Acid (Aspirin, BAYE4465)” NCT00963443 ↗ “Aspirin (Acetylsalicylic acid, BAYE4465)” NCT00501059 ↗ |
| Known as | Bayer | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)
Other Names:
Ecotrin,...” NCT01731236 ↗1“One EC aspirin (Bayer®) 81 mg tablet” NCT01557335 ↗ |
| Known as | Bayer Aspirin | “Aspirin Group: Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg...” NCT06738992 ↗1“81mg of Bayer Aspirin per oral daily” NCT06228820 ↗ |
| Known as | Bayer Genuine Aspirin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Bufferin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Cardisprin 75 | “75 mg aspirin (Cardisprin 75, Cosmos, Nairobi, Kenya)” NCT05525156 ↗ |
| Known as | D,L-lysine acetylsalicylate | “D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV” NCT00910065 ↗ |
| Known as | Durlaza | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Ecotrin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Enteric Coated Aspirin Tablet | “Drug: Enteric Coated Aspirin Tablet” NCT04330872 ↗ |
| Known as | Enteric-coated Aspirin | “Arm I: Chemoprevention. Enteric-coated Aspirin, ASA, NSC-27223.” NCT00002527 ↗ |
| Known as | Fasprin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Fast release Aspirin | “Acetylsalicylic acid (Fast release Aspirin, BAY1019036)” NCT01117636 ↗ |
| Known as | Fixed dose combination of clopidogrel/Aspirin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01663038 ↗ |
| Known as | Genacote | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Halfprin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | Hjertemagnyl | “EPO + ASA Treatment Aranesp treatment is supplemented with ASA (Hjertemagnyl ® 75 mg x 1 daily).” NCT04330729 ↗ |
| Known as | I-ASA | “The goal of this clinical trial is to compare the pharmacokinetics (PK) pharmacodynamics (PD), safety and tolerability of acetylsalicylic acid powder for oral inhalation...” NCT05625347 ↗ |
| Known as | IR-ASA | “We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL-ASA compared with immediate release aspirin (IR-ASA).” PMID 31420787 ↗ Nov 2019 |
| Known as | juspirin | “Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.” NCT04168398 ↗ |
| Known as | LD EC-ASA | “Bayer® low-dose enteric-coated aspirin 81 mg tablets (LD EC-ASA)” PMID 39008026 ↗ Jul 2024 |
| Known as | LD PL-ASA | “Vazalore® low-dose phospholipid-aspirin liquid-filled 81 mg capsules (LD PL-ASA)” PMID 39008026 ↗ Jul 2024 |
| Known as | LDA | “The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and...” NCT07658989 ↗3“The aim of the present randomized study was to determine whether TRUS-guided PB performed in patients continuing low-dose aspirin (LDA) is associated with a greater incidence,...” NCT02744937 ↗ “Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.” NCT05253781 ↗ “Anti-aggregation therapy, including treatment with low-dose aspirin (LDA) is an established risk factor for intracranial hemorrhage” NCT01470040 ↗ |
| Known as | LDASA | “Low-dose aspirin (LD-ASA) is commonly prescribed to prevent PE and confers a consistently positive effect on mitigating PE risk when given in early gestation to women at risk.” NCT04243278 ↗1“Administration of low-dose acetylsalicylic acid (LDASA) has shown to improve maternal and perinatal outcomes” NCT05073718 ↗ |
| Known as | Low-dose aspirin | “Low-dose aspirin (LD-ASA) is commonly prescribed to prevent PE and confers a consistently positive effect on mitigating PE risk when given in early gestation to women at risk.” NCT04243278 ↗ |
| Known as | Norwich Aspirin | “Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study) Other Names: Ecotrin,...” NCT01731236 ↗ |
| Known as | NSC-27223 | “Arm I: Chemoprevention. Enteric-coated Aspirin, ASA, NSC-27223.” NCT00002527 ↗ |
| Known as | PL2200 | “Patients were exposed to three 325-mg aspirin formulations: plain aspirin, PL2200 (a modified-release lipid-based aspirin), and a delayed-release enteric-coated (EC) aspirin.” PMID 28089180 ↗ Jan 20171“Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)” NCT02008942 ↗ |
| Known as | Plain Aspirin | “Drug: Plain Aspirin” NCT04330872 ↗ |
| Known as | Trombyl | “Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)” NCT00789308 ↗ |
| Known as | UI1610477 | “Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)” NCT06655194 ↗ |
| Known as | UI1615160 | “Acetylsalicylic Acid (BAYE004465, UI1615160)” NCT06655194 ↗ |
| Known as | Vazalore Aspirin | “81mg Vazalore Aspirin per oral daily” NCT06228820 ↗ |
| Known as | VTS-Aspirin | “Patients were randomized to receive either 324 mg of VTS-Aspirin™ and 0.5 mg/kg of oral ketamine (AOK) that is directly swallowed or 0.5 mg/kg of oral ketamine (OK) alone that...” PMID 35777275 ↗ May 2022 |
| Action | Inhibit | “Aspirin, in small doses, inhibits platelet aggregation for prolonged periods of time” NCT00000491 ↗ |
| Modality | Small molecule | “a widely available and prototypical non-steroidal anti-inflammatory agent, aspirin” NCT01797575 ↗ |
| Route | Oral | “pre- and post-operative oral administration of platelet-inhibiting drugs” NCT00000527 ↗ |
| Target | PTGS1 | “Suboptimal inhibition of platelet cyclooxygenase 1 (COX-1) by aspirin” PMID 24022862 ↗ Feb 2014 |